Innate immune defence to Helicobacter pylori. by Boughan, P.K.
Innate Immune Defence to Helicobacter pylori
By
Parjeet Kaur Boughan
A thesis submitted for the degree of Doctor of Philosophy
University of London
February 2007
Infectious Diseases and Microbiology Unit 
Institute of Child Health 
University College London
UMI Number: U591857
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
Dissertation Publishing
UMI U591857
Published by ProQuest LLC 2013. Copyright in the Dissertation held by the Author.
Microform Edition © ProQuest LLC.
All rights reserved. This work is protected against 
unauthorized copying under Title 17, United States Code.
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106-1346
Abstract
Helicobacter pylori exhibits tropism for the human stomach causing a spectrum of 
complications ranging from gastritis to gastric cancer in susceptible individuals. The 
mechanism(s) that allow the bacteria to persist and cause disease are unfolding, 
p-defensins are a family of endogenous, epithelial anti-microbial peptides that engage in 
host defense most prominently at mucosal surfaces. We and others have previously 
shown that human p-defensin (hBD)-2 and -3 are potent bactericidal agents against H. 
pylori. At present the identity of signalling pathways involved in host-bacterial cross talk 
leading to modulation of host antimicrobial immunity are unknown.
The present study firstly investigated the potential role of bacterial virulence factors in 
mediating human p-defensin gene expression during H. pylori infection. AGS gastric 
epithelial cells were infected with cytotoxic H. pylori strains (60190, 84-183) and 
isogenic mutant strains (cagA-, cagE-, vacA- and CagPAl-). Human p-defensin (hBD2 & 
-3) gene expression quantified by RT-PCR and p-defensin transcriptional regulation was 
followed by transient transfection studies utilising hBD2 and -3 promoter luciferase 
constructs. We found hBD2 induction was dependent upon an intact cagVAl and minimal 
involvement was observed for the bacterial virulence factors CagA and VacA in 
modulating P-defensin expression.
We sought to investigate the bacterial component responsible for instigating epithelial 
innate immune responses. Through the use of siRNA for NODI we determined a role for 
NODI-dependent NF-kB activation in mediating hBD2 but not hBD3 expression. 
Experiments utilising specific inhibitors of the MAP Kinase pathways directed us to 
delineate the role of each pathway in modulating p-defensin expression by the activation 
of stably transfected conditional MAP Kinase mutants. These studies revealed critical 
involvement of ERK pathway in the regulation of hBD3 but not hBD2 gene expression.
Signalling upstream of ERK was explored and revealed EGFR as the host receptor 
responsible for detection and initiation of hBD3 gene and peptide production.
Our studies demonstrated a crucial role for NODI in H. pylori-mediated hBD2 but not 
hBD3 expression and implicate EGFR transactivation in mediating hBD3 but not hBD2 
expression, thus indicating two distinct regulatory mechanisms at play during innate 
immune host response to H. pylori infection.
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CHAPTER 1 
Introduction
1.0 Helicobacter pylori
1.1. Discovery of a Campylobacter-like organism
Marshall and Warren were the first to report the presence of Campylobacter-like organism 
in the stomach lining of patients with chronic gastritis and peptic ulcers (Marshall and 
Warren, 1984). In 1984, the name Campylobacter pyloridis was proposed and urease 
production by the bacterium was established. The presence of urease allowed the detection 
of the bacterium in gastric biopsies (McNulty and Wise, 1986) and even today forms the 
basis of clinical diagnostic tests.
Comparison of C. pyloridis gene sequences with other members of the Campylobacter 
family led to the bacterium being designated to a new genus called Helicobacter and C. 
pyloridis was referred to as Helicobacter pylori (Maddocks, 1990). Completion of the 
genome sequences of two H. pylori strains 26695 and J99 (Aim et al., 1999) has allowed 
more detailed microbiological characterisation of the organism.
H. pylori is a spiral shaped, Gram-negative, microaerophilic bacillus, but coccoidal forms 
have also been reported under a variety of conditions including nutrient deprivation and 
antibiotic stress (Figure 1.1). Both forms are believed to be infectious, the clinical 
significance of the coccoid form remains unclear.
I.2 Pathogenesis and Clinical Associations
Helicobacter pylori is a highly successful extracellular mucosal pathogen that colonises the 
gastric epithelium causing persistent inflammation (chronic active gastritis). It exhibits 
selective tropism for the gastric mucosa or sites of gastric metaplasia and does not colonise 
regions of the stomach undergoing intestinal metaplasia (Figure 1.2; Ernst et al., 2006, 
Peterson, 1991, Suerbaum and Michetti, 2002). It infects up to 50% of the population 
worldwide, yet only a proportion of susceptible individuals develop clinical complications
Figure 1.1: H. pylori (spiral and coccoidal) adhering to gastric epithelium (from 
Marais et al., 1999).
Figure 1.2: Histological identification of H. pylori in a gastric mucosal biopsy. Arrows 
indicate the presence of H. pylori adjacent to the gastric epithelium (from Ernst et al., 
2006).
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(Montecucco and Rappuoli, 2001). Variation observed in clinical outcome of H. pylori 
infection is now known to be influenced by the virulence of the infecting strain (Figure 1.3; 
Atherton et al., 1997a, Blaser and Crabtree, 1996) susceptibility of the host (El-Omar et al., 
2000) and environmental factors (Blaser and Atherton, 2004). The clinical course of H. 
pylori infection ranges from peptic ulceration to distal gastric adenocarcinoma and gastric 
mucosal lympho-proliferative diseases such as MALT lymphoma (Nomura et al., 1991, 
Parsonnet et al., 1994, Peterson, 1991, Suerbaum and Michetti, 2002).
A correlation between the pattern and distribution of gastritis and subsequent complications 
has been noted. Patients with antral-predominant gastritis (the most common form) are 
predisposed to duodenal ulcers, whereas patients with corpus-predominant gastritis and 
multifocal atrophy are more predisposed to gastric ulcers, gastric atrophy, intestinal 
metaplasia and ultimately gastric carcinoma (Suerbaum and Michetti, 2002). The majority 
of gastric and duodenal ulcers result from H. pylori infection and the lifetime risk of 
development of peptic ulcer for H. pylori carriers varied from 3% in United States to 25% 
in Japan (Schlemper et al., 1996).
Gastric infection with Helicobacter pylori causes mucosal inflammation that is 
concentrated in the gastric antrum. This pattern of inflammation is referred to as type B 
gastritis and although type B gastritis is most intense in the antrum, it commonly coexists 
with a* less severe inflammation in the fundus. Almost all (95%) patients who have this 
pattern of gastritis will concurrently be infected with H. pylori (Blaser and Atherton, 2004). 
The mechanism regarding formation of duodenal and gastric metaplasia is believed to be in 
response to acid exposure, thus leading to direct epithelial damage or secondary 
inflammation. This acid release derives from parietal cells resulting from histamine binding 
to histamine-type 2 receptors. The histamine is released after G-cells produce gastrin 
(Dockray et al., 2001).
Fnviron m ental f w lo n
(smoking, high salt, 
vitamin C, fi-carotene)
/ /  pylori factors
(virulcmxs lielors)
ACID OUTPUT
INFLAM M ATION
Host factor*
(gene polymorphisms, 
immune resnonsei
Chiooic gastritis
Gastric or duodena 
ulcer disease
MALT-lymphoma
uronhic tsastritts ~ Gastric cancer
Figure 1.3: Contribution of factors influencing H. pylori disease outcome (taken from 
van Amsterdam et al, 2006).
These injured duodenal areas may heal by acquiring gastric epithelium, which might be 
better adapted than duodenal epithelium for acid exposure. After gastric metaplasia has 
occurred, these areas are likely to provide a site for bacterial adherence, thus contributing 
to the pathogenesis of duodenal ulceration.
Carcinoma of the stomach is the second most common cause of cancer death worldwide 
(Montecucco and Rappuoli, 2001) and implication of H. pylori as a key risk factor for the 
development of gastric carcinoma has been recognized through many clinical studies, first 
described by Parsonnet et a im  1991. As a result, H. pylori has been classified as a group I 
carcinogen by the International Agency for Research on Cancer (IARC) in 1994. Most 
notably, mucosa-associated lymphoid tissue (MALT) lymphomas account for 
approximately 5% of all gastric cancers (Lacy and Rosemore, 2001), and is particularly 
significant as it usually goes into complete remission upon eradication of the pathogen 
(Bayerdorffer et al., 1995). This is also true for peptic ulcers as eradication of the organism
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caused a drastically lower recurrence rate of H. pylori-'mduced peptic ulcers (Marshall et 
al, 1988).
Conversely, evidence suggests that in some populations, H. pylori-induced chronic 
gastritis, especially when localised to the acid-secreting corpus, is associated with a 
reduced risk for developing gastro-oesophageal reflux disease, Barrett’s oesophagus, and 
Barrett’s-associated oesophageal adenocarcinoma (Dent, 1999). H. pylori has also been 
implicated in the pathogenesis of many extragastric diseases, extending from 
atherosclerosis to skin diseases but documentation is limited (Howden and Leontiadis, 
2000).
1.3 Epidemiology and Transmission
Incidence of Helicobacter pylori infection is worldwide; however prevalence varies 
amongst age groups, ethnic groups and among countries. For example, approximately 30% 
of the developed countries and up to 80% of the developing world is infected (Figure 1.4; 
Atherton, 1997a). Overall occurrence is strongly correlated with socioeconomic conditions 
(Malaty and Graham, 1994), poor sanitation and hygiene being major risk factors. Most 
infections appear early in life, with infection rate independent of gender (Lacy and 
Rosemore, 2001). In adults of higher socioeconomic groups the prevalence of 
seropoSitivity increases with age to eventually reach 40% or more; and this increase is due 
to low but cumulative risk of acquisition in Western countries in past years than a recent 
event, representing cohort effect (Cullen et al., 1993).
In industrialised countries direct transmission from person to person via vomitus, saliva, or 
faeces is the predominant route of transmission, whereas additional routes such as water 
may be important in developing countries (Goodman et al., 1996, Parsonnet et al., 1999). 
Despite the stomach being the natural habitat, H. pylori has been found in dental plaque
Figure 1.4: Epidemiology of H. pylori infection.
The prevalence of H. pylori colonisation correlates with socio-economic status 
(Helicobacter foundation website, 2004)
and saliva (Nguyen et al., 1995). Although there is no evidence to suggest zoonotic 
transmission, the bacterium has been detected in nonhuman primates and other animals 
(Dore et al., 2001, Handt et al., 1994).
1.4 Contribution of bacterial and host factors to disease pathogenesis
H. pylori is very much adapted to the ecological niche of the stomach. Despite the acid 
environment, peristalsis and the induction of local immune responses the organism 
colonises and can persist in this micro-environment for decades (Valle et al., 1996). 
Bacterial virulence factors aid the pathogen not only to penetrate the mucous layer but also 
to allow attachment to the epithelial cells and furthermore, evade the host immune response
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to permit colonisation (Blaser and Atherton, 2004). The bacterium is also highly competent 
in DNA uptake from other strains (Suerbaum et al., 1998) and therefore, there is continual 
generation of diversity to overcome host restraints.
1.4.1 Bacterial virulence determinants
1.4.1.1 Flagella
The bacterium achieves rapid motility and spreading through the mucosal barrier of the 
stomach via its flagella. Each bacterium possesses five or six uniploar, sheathed flagella 
(Figure 1.5) which are protected from stomach acid by a double layer of phospholipids. 
Flagellar filaments are composed of two proteins, FlaA and FlaB. Differential activation of 
the two genes suggests composition of the flagella may vary depending on dictating 
environmental conditions (Josenhans et al., 1995).
Figure 1.5: H. pylori - a gastric pathogen.
(Courtesy of Dr Andrew Harris, Bart’s and the Royal London Medical School, UK)
1.4.1.2 Urease
Urease is essential for the virulence and successful colonisation of the bacterium (Eaton et 
al., 1991). Animal studies have shown that urease-negative H. pylori mutants do not 
colonise the gastric mucosa (Tsuda et al., 1994). The enzyme breaks down urea (present in 
gastric juice and extracellular fluid) into ammonia and bicarbonate (Israel and Peek, 2001). 
Ammonia alkalinises the microenvironment to allow H. pylori to survive in gastric acid and 
colonise (Mobley, 2001). Enzyme activity is regulated by a unique pH-gated urea channel, 
Urel, which opens at low pH and increases permeability of the bacterial membrane to urea 
but prevents influx of urea under neutral condition (Weeks et al., 2000).
1.4.1.3 Adhesins
The majority of H. pylori colonising gastric mucosa are free-living, with an approximate 
20% binding intimately to gastric epithelia (Clyne and Drumm, 1993). BabA is a well- 
characterised bacterial ligand involved in host cell recognition and binding. BabA is a 
78kDa membrane-bound adhesin encoded by the gene babA2 and it binds to fiicosylated 
Lewis B blood group antigen present on epithelium (liver et al., 1998). H. pylori babA2+ 
strains are linked to an increased risk for duodenal ulceration and gastric adenocarcinoma, 
whereas strains deficient in babA2 are more likely to cause gastritis alone (Gerhard et al., 
1999). These findings have been verified in a transgenic mouse model expressing Lewis B 
antigen (Guruge et al., 1998). Recent studies have demonstrated that selection of BabA 
variants with increased or decreased adherence to Lewis B antigens may play a role in host 
adaptation (Aspholm-Hurtig et al., 2004, Solnick et al., 2004).
Although BabA is the most studied adhesin, several other adhesion-related factors are 
likely to play a role in bacterial adherence. Absence of HopZ leads to decreased bacterial 
binding (Peck et al., 1999). HpaA (HP0410) binds to host sialylated glyconjugates (Evans 
et al., 1993), AlpA and AlpB are also significant adhesins (de Jonge et al., 2004, Odenbreit
et al., 2002), which unlike BabA are found in nearly all bacterial strains, implying a 
contributory role in bacterial colonisation (Odenbreit et al., 1999).
1.4.1.4 Lipopolysaccharide (LPS)
Lipopolysaccharides comprise a major component of the cell wall of Gram-negative 
bacteria. The low immunological and endotoxic activity of H. pylori LPS has been 
confirmed both in animal and cell culture models (Ferrero, 2004, Smith et al., 2003). 
Despite reduced activity, H. pylori LPS does demonstrate some effects on gastric mucosa.
H. pylori LPS from type I strains can induce apoptosis in guinea-pig gastric cells 
(Kawahara et al., 2001) and induce endoethelin and TNF-a (Ierardi et al., 2003). H. pylori 
LPS affects mucin synthesis and pepsinogen secretion, which may further contribute to the 
pathogenesis of H. pylori related diseases (Moran et al., 1996).
LPS represents an important component of Gram-negative bacteria. It comprises a 
polysaccharide O-antigen chain (a core oligosaccharide) and a lipid moiety (lipid A) that 
anchors the LPS molecule to the outer membrane (Raetz and Whitfield, 2002). Unlike other 
Gram-negative bacteria, H. pylori post-translationally modifies its O-antigen by undergoing 
fucosylation, hence displaying mimicry to Lewis antigens present on human epithelial cells 
(Monteiro et al., 2000). Detailed mechanistic studies have revealed H. pylori LPS variation 
in fucosylation patterns allow the micro-organism to evade innate and adaptive host 
immunity (Nilsson et al., 2006). An example of this subversion is highlighted by 
examination of a pattern recognition receptor, surfactant protein D (SP-D) which binds 
directly to LPS of Gram-negative bacteria via the carbohydrate recognition domain (Kuan 
et al., 1992). SP-D is present in the gastric mucosa and expression increases in individuals 
infected with H. pylori (Murray et al., 2002). Further analysis of the interaction of SP-D 
with H. pylori LPS revealed the ability of O-antigen modifications to evade innate immune 
recognition, contributing to bacterial persistence (Moran et al., 2005).
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1.4.1.5 Helicobacter pylori- Neutrophil Activating Protein (HP-NAP)
One of the hallmarks of H. pylori infection is extensive neutrophil infiltration and ensuing 
tissue damage (Fiocca, 1994, Satin, 2000). Helicobacter pylori- Neutrophil Activating 
Protein (HP-NAP) is a 150kDa dodecameric iron-binding protein that adheres to human 
neutrophils and endothelial cells leading to production of reactive oxygen radicals (Evans 
et al., 1995, Yoshida, 1993). Recombinant HP-NAP exhibits chemotactic activity for 
human neutrophils and monocytes, a potential mechanism H. pylori may utilise to 
modulate host phagocytic activation (Satin, 2000). All H. pylori strains investigated to date 
contain the gene encoding HP-NAP, although protein levels show marked variation (Evans 
and Harmon, 1995). Clinical and pathogenic consequences of HP-NAP protein levels 
remain unclear.
1.4.1.6 Vacuolating cytotoxin (VacA)
VacA is a secreted 95kDa exotoxin which is expressed in an active form by approximately 
50% of H. pylori strains (Leunk et al., 1988). This multimeric pore-forming protein induces 
vacuole formation in cultured epithelial cells (Figure 1.6) and causes epithelial damage 
when administered to mice (Telford et al., 1994). Vacuoles arise in the perinuclear area and 
enlarge in size to fill the entire cytosol, eventually leading to death by necrosis (Figura et 
al., 1989). This vacuolar degeneration of host cells is achieved by interference of 
intracellular membrane fusion and the vacuoles produced appear to be a hybrid between 
lysosomal and late endosomal compartments (Covacci et al., 1999).
Low pH allows the disassociation of the inactive oligomeric VacA protein into active 
monomers, the latter being resistant to both acid and pepsin. These biochemical properties 
emphasise the toxin’s suitability to the gastric milieu (de Bernard et al., 1995). The
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(a) (b)
Figure 1.6: Effects of vacuolating toxin on AGS gastric epithelial cells (a) untreated 
cells; (b) VacA treated cells.
(Courtesy of Prof J.C Atherton, University of Nottingham, UK)
exotoxin inserts itself into the epithelial membrane forming hexameric anion-selective, 
voltage dependent channels, allowing release of cytosolic bicarbonate and organic anions 
(Szabo et al., 1999). Furthermore, VacA toxin modifies tight junctions, increases 
permeability for iron, nickel and other nutrients, essential for H. pylori growth and urease 
activity (Montecucco and Rappuoli, 2001). In addition to vacuole generation, VacA also 
affects cells directly in vitro by inducing cytoskeletal changes, apoptosis, and suppression 
of epithelial cell proliferation and migration (Cover et al., 2003, Kuck, 2001, Pai et al.,
1999). All strains possess the vacA gene but there is significant strain-dependent sequence 
variation in the VacA protein particularly in the mid-region (ml or m2) and in the signal 
sequence (sia, s ib  or s2). H. pylori strains carrying different combinations of both regions 
have been isolated (Atherton et al., 1995, Letley and Atherton, 2000). Strains expressing
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sl/ml generally secrete high protein levels, ml strains are more active than m2, si a type is 
more effective than sib and s2 doesn’t produce detectable activity (Atherton et al., 1997b, 
Blaser and Atherton, 2004). Transcription for vacA induction occurs in proximity to 
epithelial cells in vitro, highlighting importance for VacA in bacterial-host cell interactions 
(van Amsterdam et al., 2003).
Clinical studies show 30-40% of patients suffering from ulceration do not possess toxigenic 
strains (Figura et al., 1989, Tee et al., 1995). Further studies have concluded that a vacA si 
genotype confers greater likelihood for ulcer disease than an sib or s2 genotype (Atherton, 
1997b).
1.4.1.7 Cytotoxin- associated gene Pathogenicity Island
Of all bacterial virulence factors implicated in disease pathogenesis, the Cytotoxin- 
associated gene pathogenicity island (CagPAI) is the most prominent (Censini et al., 
1996). H. pylori strains are termed cag+ (virulent) or cag- (less virulent) depending on the 
presence of this 40kb genomic fragment region, comprising approximately 30 genes 
(Censini et al., 1996). The role of cagPAI in disease pathogenesis has been confirmed in 
the Mongolian gerbil model of infection, where cag+ H. pylori caused severe 
inflammation, and further gastric complications typical of H. pylori infection, compared to 
animals colonized with cag- strains which were affected with mild asymptomatic gastritis 
(Ogura et al, 2000).
The pathogenicity island encodes a type IV secretion apparatus, homologous to those found 
in other bacteria, including the Ti plasmid transfer system of Agrobacterium tumefaciens 
and the pertussis toxin secretion machinery of Bordetella pertussis (Covacci and Rappuoli, 
2000). This export machinery is required for translocating the bacterial cytotoxin- 
associated antigen, CagA, protein into host cells (Odenbreit et al., 2000). Although cagA is 
often used as a marker for the whole cag?Al, recent evidence suggests the presence of
cagA does not necessarily correlate with an intact cargPAI (Censini et al., 1996, Covacci et 
al., 1993, Salama et al., 2000). While this immunodominant protein is present in 60-70% of
H. pylori strains (Akopyants et al., 1998), it is prevalent in 50-60% of patients suffering 
from gastritis and in 88-100% of bacterial isolates in patients with duodenal ulceration 
(Covacci et al., 1993).
Cellular investigations into the function of CagA, a 128-145kDa protein showed the 
injected protein on entering host cells was rapidly phosphorylated (Asahi et al., 2000, Segal 
et al., 1999). Phosphorylated CagA allows recruitment of SHP-2 (a tyrosine phosphatase) 
to the cellular membrane, leading to actin polymerization and pedestal formation (Covacci 
and Rappuoli, 2000). The net result of these molecular interactions is a distinct change in 
the phenotype (humming-bird) of the infected gastric epithelia (Segal et al., 1999). 
Phosphorylated CagA has been implicated in increased frequency of gastric cancer cases 
where patients are infected with cag+ strains (Covacci and Rappuoli, 2000). Specifically,
H. pylori strains inducing higher levels of CagA phosphorylation, owing to increased 
number of tyrosine phosphorylation motifs (TPMs), are more likely to be associated with 
gastric cancer (Argent et al., 2004). Proto-oncogenes c-fos and c-jun are known to be 
activated in gastric epithelial cells infected with cag+ strains and may correspond to a 
critical step in the development of neoplasia (Meyer-ter-Vehn et al., 2000).
I.4.2 Genetic Host factors
As discussed above, there are several bacterial determining factors influencing the outcome 
of H. pylori-related diseases. Studies investigating the effect of strain variation have 
revealed that even the most virulent (CagA+, CagPAI+) H. pylori strains can be harboured 
by asymptomatic individuals (Ernst et al., 2006). This indicates the important contribution 
of host factors in modulating pathogenesis and disease outcome (El Omar et al., 2000, El 
Omar et al., 2001, El Omar et al., 2003, Kim et al., 2006).
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Polymorphisms in host cytokine genes such as IL-lp, IL-1 receptor antagonist (IL-1RA), 
IL-10 and TNFa have been linked to gastric cancer progression (Chakravorty et al., 2006, 
El Omar et al., 2000, El Omar et al., 2003, Machado et al., 2001, Wu et al., 2003, Yea et 
al., 2001). Specifically, a polymorphism (a C-T base transition) at position -31 in the 1L-1B 
gene results in gastric cancer in approximately 31% of the study population. Functionally, 
this polymorphism induced a 5-fold induction in transcriptional activity of factors 
regulating IL-lp production in response to LPS in vitro (El Omar et al., 2000). 
Polymorphisms may lead to an increase in pro-inflammatory (IL-lp, TNFa) cytokines or 
inadequate anti-inflammatory (IL-10) cytokine release which can result in gastric mucosal 
damage owing to a Thl biased inflammatory response (Eaton et al., 2001, El Omar et al.,
2003). This response affects acid secretion as the cytokines IL-1 P and TNFa prevent 
parietal cells from producing acid (Beales and Calam, 1998, Padol and Hunt, 2004, 
Takashima et al., 2001), which in turn may allow persistence and spread of H. pylori 
(Bjorkholm et al., 2004).
Presence of multiple cytokine polymorphisms and infection demonstrate a synergistic 
increase in risk of gastric cancer (El Omar et al., 2003). Additionally, in a study of African 
subjects, IFNyRl polymorphisms were implicated in determining susceptibility of 
individuals to H. pylori infection (Thye et al., 2003), which may aid toward reasoning the 
high prevalence of infection but low incidence of cancer (the ‘African enigma’) 
(Holcombe, 1992).
1.5 Host Innate Immunity
Although it is clear that H. pylori possesses and utilises several virulence determinants to 
ensure its survival, the bacterium is also able to manipulate host immune responses to allow 
persistence in the stomach. For example, by the induction of certain antimicrobial peptides
such as (3-defensin 2 and LL-37, H. pylori may attempt to defend its gastric niche from 
other potential pathogens or limit its own proliferation so it may control nutrient 
acquisition. Other mechanism(s) by which H. pylori subverts host immunity are discussed 
below.
1.5.1 Epithelial cells
The establishment of NF-kB activation by H. pylori infection has since led to studies 
detailing specific signalling components involved in this signalling cascade, most notably 
the identification of Nucleotide-binding Oligomerisation Domain-1 (NODI) as the host 
pattern recognition receptor (Hirata et al., 2006, Hirata et al., 2006, Maeda et al., 2000, 
Mori et al., 2003). Although, both IkB kinase (IKK) and NF-icB-inducing kinase (NIK) are 
key upstream signal transduction players implicated in H. /7y/or/-mediated NF-kB 
activation (Hirata et al., 2006, Maeda et al., 2000, Mori et al., 2003, Viala et al., 2004), 
involvement of the adaptor protein myeloid differentiation factor 88 (MyD88) and tumour 
necrosis factor a-associated factor 6 (TRAF6) remains controversial, as one study suggests 
no role for TRAF6 in NF-icB-mediated Regulated upon Activation, Normal T cells 
Expressed and Secreted (RANTES) expression (Mori et al., 2003) but other studies 
implicate TRAF6 in H. pylori-mediated NF-kB activation (Hirata et al., 2006, Maeda et al.,
2000). H. pylori- mediated signalling pathways involved in NF-kB activation are a subject 
of active research.
1.5.2 Other innate cells
Epithelial cells provide the first line of defence and form a critical component of innate
defence. It is well established that IL-8 produced by epithelial cells in response to H. pylori
chemoattracts neutrophils to the site of infection. Activated neutrophils present in the
inflamed gastric mucosa produce reactive oxygen and nitrogen species which cause damage
to host tissue (Crabtree, 1996). H. pylori avoids being harmed by free radicals by producing
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enzymes involved in reactive oxygen intermediates (McGee and Mobley, 1999) and by 
doing so the bacterium is able to prevent microbicidal effects in addition to causing tissue 
damage.
Macrophages produce iNOS (inducible nitric oxide synthase), in response to H. pylori 
leading to cell injury and apoptosis (Wilson et al., 1996). Nitric Oxide (NO) is known to 
exhibit microbicidal effects. As bacterial expressed arginase and iNOS share the substrate, 
L-arginine, H. pylori manages to escape killing by NO by regulating NO synthesis (Gobert 
et al., 2001). Macrophages exposed to an isogenic mutant lacking arginase were found to 
be more susceptible to killing by NO compared to wild type strain (Baldari et al., 2005). 
This avoidance of bactericidal activity of macrophages clearly provides at least one 
mechanism by which H. pylori is able to subvert host immunity.
1.6 Infection models
In order to strengthen in vitro findings and obtain a clearer view of host immune responses
in vivo, several animal infection models have been investigated. Recent transcriptional
profiling analyses in murine models have revealed gastric cells respond to H. pylori
infection by induction of inflammatory genes including IL-1 (3 and RANTES (Mueller et al.,
2004). Furthermore, similar transcriptional profiling studies in the rhesus macaque model
resulted in significant induction of immune and inflammatory genes such as P-defensin 2,
chemokine receptor 2 and protease inhibitor 3 (Huff et al., 2004). These studies provide
valuable insight into the programmed transcriptional response to bacterial infection in vivo.
Transgenic mice and specified genotypes make murine models an obvious choice for
studying H. pylori pathology in vivo, unfortunately wild type mice are not as susceptible to
H. pylori, and infection does not lead to pathology as observed in human disease (Court et
al., 2002). A murine pathogen, H. felis has replaced H. pylori in many studies as it causes
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more severe inflammation (Court et al., 2002, Sakagami et al., 1996). This strain, however, 
lacks many important virulence determinants such as the cagPAl and VacA (Ernst et al., 
2006) highlighting limitations of such studies.
In contrast to mouse models, the Mongolian gerbil is more susceptible to H. pylori 
infection, causing gastric pathology similar to that observed in human disease (Crabtree et 
al., 2004, Ogura, 2000, Peek, Jr. et al., 2000, Watanabe et al., 1998, Zheng et al., 2004). 
Progression from colonisation to gastric adenocarcinoma in gerbils has been limited to 
studies from Japan and China (Peek, Jr. and Crabtree, 2006) and a recent study 
investigating the potential of certain strains becoming more carcinogenic after passages in 
vivo yielded interesting findings (Franco et al., 2005). A single colony from a gerbil 
infected with H. pylori strain B128 for 3 weeks was used to infect independent gerbils. 
Despite the parent gerbil not presenting with gastric adenocarcinoma, 75% of the newly 
colonised gerbils had gastric adenocarcinoma 8 weeks post-infection (Franco et al., 2005). 
These results demonstrate the ability of H. pylori to cause gastric cancer in the Mongolian 
gerbil model and therefore highlight a suitable model to study disease pathogenesis.
1.7 Adaptive Immunity
Although the gastric epithelium is the main point of microbial contact for the extracellular
H. pylori, increasing impairment of epithelial integrity during on-going infection, must
allow the bacterium to interact with underlying antigen-presenting cells and phagocytes.
Dendritic cells (DCs) are potent antigen-presenting cells and important mediators between
the innate and acquired immune system, to date there have been few studies investigating
DC maturation in response to H. pylori infection (Guiney et al., 2003, Kranzer et al., 2004,
Voland et al., 2003). Stimulation of DCs with H. pylori results in IL-6, IL-8, IL-10 and IL-
12 production (Guiney et al., 2003, Kranzer et al., 2004) and further investigations suggest
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Cag?PA and VacA independent mechanism(s) of activation and maturation are operative 
(Kranzer et al., 2005).
1.7.1 Cell-mediated immunity
There are two functional subsets of CD4+ T lymphocytes, T helper 1 (Thl) and T helper 2 
(Th2), which have distinct cytokine profiles. Thl cells are known to enhance cell-mediated 
immunity whereas production of Th2 cells induce B cell activation and differentiation 
(humoral immunity) (Israel and Peek, Jr., 2006). Although a novel, pathogenic Th-17 T cell 
subset has been identified recently (Veldhoen and Stockinger, 2006), no studies 
investigating the role of this subset in H. pylori induced disease have yet been reported.
Thl type responses are stimulated in response to most intracellular bacteria whereas Th2 
responses are induced by extracellular pathogens (Portal-Celhay and Perez-Perez, 2006). 
Considering this, one would expect Th2 type responses to H. pylori to predominate since it 
is largely a non-invasive bacterium, but this is not the case. H. pylori infection in both 
humans and animal models exhibits a predominant Thl profile, with increased levels of 
IFNy (Bamford et al., 1998, Crabtree et al., 2004). The cytokine expression profiles have 
been documented in gastric mucosa of infected H. pylori individuals including children 
(Luzza et al., 2001). Interestingly, a recent study exploring H. pylori-mediated effects on 
IFNy signalling revealed disruption of signal transducer and activator of transcription 1 
(STAT1) signalling (Mitchell et al., 2004). Another strategy by which H. pylori achieves 
Thl polarisation may be by suppression of IL-4, a Th2 cytokine, by a cag?Al and Vac 
independent mechanism (Ceponis et al., 2003). By interfering with host signalling, the 
bacterium seems to manipulate a Thl rather than Th2 bias and successfully evade complete 
clearance.
The above mechanism(s) have not identified bacterial factors responsible for the Thl
profile; however, a very recent investigation implicates HP-NAP in directly modifying host
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immunity (Amedei et al., 2006). HP-NAP increased IFNy, reduced IL-4 in addition, 
neutrophil and monocyte dependent induction of IL-12 and IL-23 was noted, resulting in an 
overall Thl cytokine profile (Amedei et al., 2006). This Thl bias was also observed in vivo 
in human gastric mucosa in response to H. pylori infection.
1.7.2 Antibody immunity
H. pylori infection results in vigorous IgG and IgA antibody production both in serum and 
gastric mucosa (Bhat et al., 2005, Crabtree et al., 1993, Luzza et al., 1995) but despite this, 
infection still persists. In vitro phagocytosis and killing of H. pylori by polymorphonuclear 
leukocytes was enhanced by binding to IgG (Tosi and Czinn, 1990). H. pylori activates and 
is susceptible to both the classical pathway, even without antibodies, and the alternative 
pathway of complement (Berstad et al., 2001, Gonzalez-Valencia et al., 1996). An 
investigation into the role of mannan-binding lectin (MBL), which also promotes 
phagocytosis and activates complement by the lectin pathway found no association between 
MBL deficiency and H. pylori gastritis (Bak-Romaniszyn et al., 2006).
Infection studies in B cell deficient mouse models show that initial bacterial colonisation is 
similar in both wild type and B cell K/O mice. In contrast, prolonged infection results in 
clearance of bacteria with more severe gastritis in B cell K/O mice but not in wild type 
litter (Akhiani et al., 2004), suggesting the presence of antibodies does not confer 
protection but rather are detrimental to successful bacterial elimination.
Further studies from the same researchers utilising IL-10 and IgA deficient mice revealed 
markedly less colonisation when compared to wild type mice, which re-iterates earlier 
findings that antibodies do not eliminate infection, allowing colonisation and persistence 
(Akhiani et al., 2005). These investigations provide conclusive evidence that antibody 
production does not confer protection against H. pylori but rather the presence of IgA in 
particular, enables the pathogen to evade host immune responses.
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1.8 Vaccines
Despite H. pylori being a human pathogen, some strains have been adapted to allow studies 
in animal models. Mice and gerbils have been particularly useful in vaccine studies (Del 
Giudice et al., 2001). Vaccines to date have been based on urease, CagA, VacA, NAP and 
whole cell killed bacteria (Corthesy-Theulaz et al., 1995, Hatzifoti et al., 2004, Hatzifoti et 
al., 2006, Keller and Michetti, 2001).
The oral route of vaccine administration in humans has proved to be most effective in the 
stimulation of antigen-specific IgA antibody responses in the stomach and duodenum when 
compared in trials to intranasal, intrajejunal, or rectal (Johansson et al., 2004). Oral 
immunisation of urease with an adjuvant, heat-labile enterotoxin of Escherichia coli (LT), 
resulted in marked decrease in colonisation of H. pylori in the gastric mucosa of infected 
individuals (Michetti et al., 1999). This finding demonstrates that although eradication of 
the bacterium was not achieved, this vaccine was immunogenic in this cohort of patients. 
Another vaccine study comprising formalin-inactivated whole cell bacteria also with the LT 
adjuvant exhibited effects on both infected and non-infected individuals (Kotloff et al.,
2001), as proliferation and production of IFNy from Peripheral Blood Mononuclear Cells 
(PBMCs) was observed. All vaccination studies to date show reduced colonisation but not 
eradication of the organism.
1.9 Host epithelial innate defence to H. pylori
The pathogenesis of H. /77/on-mediated infection and inflammation is most likely to be 
initially triggered by the direct interaction of the bacterium with the gastric epithelial cell 
layer (Figure 1.7). Although recent studies have shown that H. pylori has the ability to 
enter epithelial cells (Kwok et al., 2002, Semino-Mora et al., 2003) the bacterium remains
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Figure 1.7 Schematic representation of the stomach mucosa colonised by Helicobacter 
pylori, showing the main virulence factors involved in colonisation and disease (from 
Portal-Celhay and Perez-Perez, 2006).
largely non-invasive adhering to the cell surface (Corthesy-Theulaz et al., 1996, Hazell et 
al., 1986). At present our understanding of why this non-invasive bacterium elicits a potent 
pro-inflammatory response leading to severe tissue damage remains unclear. Further, the 
mechanism(s) that allow the bacterium to persist in the presence o f a robust immune 
response are unknown (Bodger and Crabtree, 1998). It is becoming increasingly clear that 
bacterial infection can stimulate the gastro-intestinal (GI) epithelium to actively participate
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in host defence (Dommett et al., 2005). During the inflammatory process, the epithelium 
expresses increased levels of innate defence genes including IL-8, ICAM-1 (Crowe et al., 
1995), IL-18 (Crabtree et al., 1999a), Cox-2 (Smith et a l, 2003) and antimicrobial peptides 
(Bajaj-Elliott et al., 2002, O'Neil et al., 1999, Wada et al., 1999, Hase et al., 2003). 
Amongst host innate defence genes known to be modulated during H. /ry/on-mediated 
infection and inflammation, the role and regulation of IL-8 remains the most well 
characterised (Blaser and Crabtree, 1996). IL-8 mRNA and protein levels are elevated in 
the gastric mucosa of patients with H. pylori gastritis (Crabtree et al., 1994). The presence 
of the azgPAI in type I H. pylori strains is known to present an additional stimulus for IL-8 
production (Allen, 2001). In-vitro studies have shown that cagA-positive cytotoxic strains 
of the bacterium induce significantly higher level of IL-8 mRNA and protein when 
compared to cag/l-negative strains (Crabtree et al., 1994).
Several in-vivo studies suggest similar higher IL-8 expression in the presence of type I 
strain compared to type II strains (Peek, Jr. et al., 1995). The increased IL-8 expression 
observed in -positive H. pylori strains seems to be related to bacterial density 
(Atherton et al., 1997a). Yamoaka and co-workers explored the relationship between cagA 
positive H. pylori duodenal ulcer (DU) and non-DU patients (Yamaoka et al., 1999). The 
ability of cagA positive H. pylori to induce IL-8 in vitro was similar and independent of 
whether the strain was from a patient with DU or gastritis. In the antrum, IL-lp and IL-8 
production was closely related to bacterial density. DU patients exhibited higher bacterial 
density and cytokine levels but there was no evidence of enhanced virulence of H. pylori 
between the two groups of patients.
Bauditz and colleagues were the first to measure cytokine levels in both H. pylori positive
and negative gastritis (Bauditz et al., 1999). On the basis of the degree of inflammation the
authors found no significant difference between the levels of pro-inflammatory cytokines
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such as IL-lp, TNF-a and IL-8. These findings suggest that the presence of pro- 
inflammatory cytokines and chemokines is a non-specific host response to inflammation 
which can occur in the absence of pathogen. However in the same study the levels of IL-12 
were significantly increased in the H. pylori-positive group.
1.10 Antimicrobial peptides
Antimicrobial peptides (AMPs) are an evolutionarily ancient arsenal providing protection 
in all multicellular organisms (Zasloff, 2002a, Zasloff, 2002b). Host AMPs mediate the 
first line of defence against pathogenic insult. Since the discovery of the first antimicrobial 
peptide by Boman and colleagues (Steiner et al., 1981) more than 500 peptides have been 
identified.
In humans, two main classes of AMP families, defensins and cathelicidins are found in a 
wide variety of tissues with predominant expression in the epithelium and in circulating 
phagocytes (Table 1.1; Zasloff, 2002a, Zasloff, 2002b). Other mammalian AMPs including 
histatins (Devine, 2003), dermicidin (Schittek et al., 2001) and anionic peptide (Brogden et 
al., 1997) are restricted to a few animal species and tissues. A single animal can contain 
different classes of peptides and a number of variants in a given class. The diversity of 
AMPs reflects the magnitude of host responses required to interact with the microbial 
world. AMPs exhibit a broad range of activity against a range of microbes including Gram- 
negative and Gram-positive bacteria, fungi, protozoa and viruses (for recent reviews see 
Eckmann, 2005, Finlay and Hancock, 2004, Ganz, 2005, Lehrer, 2004, Selsted and 
Ouellette, 2005, Klotman and Chang, 2006).
1.11 Defensins
Mammalian defensins are endogenous antibiotics that play a critical role in host innate
defence. The two main classes of human defensin genes, a and p, differ in their disulphide
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Defensin ......................1_____ _ _______ f
Conventional j 
name j
\
Type] Cell source Synthesis ! Release
HNP1 ~4
iQ | Neutrophils Constitutive Degranulation
-------- 1
CD8 T cells Inducible Secretion?
HD5 ~6 a  1...........i Paneth cells Constitutive Degranulation
Mouse cryptidin
■.........i
u | Paneth cells Constitutive i Degranulation
hBD1 1 P j Keratinocytes and epithelial cells Constitutive j 
and inducible j
Secretion
hBD2 ~4 p !...........>Keratinocytes and epithelial cells Inducible Secretion
BNDBs p Neutrophils Constitutive Degranulation
Bovine TAP P Epithelial cells Inducible Secretion
RTD-1 6_____ Neutrophils, monocytes Constitutive Degranulation
Cathelicidins
...........]
Neutrophils, keratinocytes, j 
epithelial cells, mast cells, and j 
monocytes/macrophages
Constitutive 
and inducible
Degranulation 
or secretion
‘Abbreviations: HNP, human neutrophil peptide; HD, human defensin; hBD, human P- 
defensin; BNDB, bovine neutrophil-derived P-defensin; TAP, tracheal antimicrobial peptide; 
RTD-1, rhesus theta defensin-1.
Table 1.1 Cell sources and regulation of mammalian defensins and cathelicidins (from 
Yang ei al, 2004).
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pairing, genomic organisation and in their tissue distribution (Table 1.1, Figure 1.8; Froy, 
2005, Ganz, 2003, Jia et al., 2001, Selsted and Ouellette, 2005). A third class of defensin, 0 
defensin, has been isolated from macaque monkey leukocytes (Tang, 1999). 0 defensins 
have evolved in primates but are inactive in humans due to mutations encoding premature 
stop codon (Cole, 2002). Primate 0 defensins possess lectin-like properties which may 
contribute to their ability to protect cells from HIV-1 infection (Wang et al., 2003a).
1.11.1 Gene structure and tissue distribution
Human a-defensins are expressed predominantly in neutrophils where they comprise 5-7% 
of total protein content of the azurophilic granules (Ganz and Lehrer, 1998). Neutrophil a- 
defensin peptides (HNP1-4) are known to be responsible for the non-oxidative killing 
properties of these phagocytes. For many years, HNPs were thought to be expressed solely 
in polymorphonuclear leukocytes, however, recent studies suggest that monocytes and 
natural killer cells also express HNP1-3 (Chalifour et al., 2004, Mackewicz et al., 2003). 
Paneth cells of the small intestine express two members (HD-5 and -6) of the a-defensin 
family (Bevins, 2006, Jones and Bevins, 1992, Mallow et al., 1996). Increasing evidence 
suggests a potential role for intestinal peptides in maintaining low bacterial count in the 
small intestine, in protecting pluripotent stem cells and in fighting potential pathogens 
(Bevins et al., 1999, Cunliffe, 2003, Dommett et al., 2005). In addition, the presence of 
HD-5 in the human female reproductive tract (Selsted and Ouellette, 2005) indicates a 
contribution of this peptide in maintenance of a sterile environment in the reproductive 
tract. Human p-defensins are a second, closely related family of AMPs. These AMPs are 
distributed in epithelia of a large variety of tissues (Table 1.1). To date six members (hBDs) 
of this family have been characterised, although bioinformatics suggests the presence of 
potential 30 hBDs and 45 murine p-defensin genes (Morrison et al., 2003, Schutte et al., 
2002, Semple et al., 2003, Semple et al, 2005).
Erttefic a-defensin
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Figure 1.8 Representative gene and peptide structures of mammalian defensins 
(from Selsted and Ouellette, 2005). The left panel aligns a-, P-, 0-defensin genes with 
corresponding signal, pro-segment and mature defensin sections. The right panel highlights 
differing structural arrangements, in particular the position of the three disulphide bonds.
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Tracheal antimicrobial peptide (TAP) was the first p-defensin detected in bovine airway 
epithelia (Diamond et al., 1991). The first human p defensin (hBD)-l was originally 
isolated from haemofiltrate (Bensch et al., 1995) and inducible hBD2 and -3 from human 
lesional psoriatic scales (Harder et al., 1997, Harder et al., 2001). hBD4 has been identified 
in gastric antrum and in respiratory epithelia (Garcia et al., 2001). In addition, hBDl and 2 
have been found in bodily fluids such as urine, bronchial fluids, nasal secretions and saliva 
(Abiko et al., 2003, Cole et al., 1999, Cole and Waring, 2002, Ross et al., 2004, Valore et 
al., 1998). Interestingly, hBDl is also expressed by mammary gland epithelia (Tunzi et al.,
2000), and is present in human breast milk in concentrations of roughly 1-10 pg/ml (Jia et 
al., 2001). In this setting, it is likely that hBD-1 may augment neonatal host defences 
perhaps through antimicrobial effects and/or by priming the adaptive immune system at 
mucosal surfaces. hBD5 and 6 are the most recent members of the family and have been 
localised to the epididymis and airways (Kao et al., 2003, Yamaguchi et al., 2002). The 
localisation and characteristics of hBDs strongly support the hypothesis that these peptides 
play a vital role in mucosal and epithelial defence (Hancock and Scott, 2000). 
hBDl is constitutively expressed (Zhao et al., 1996) whereas hBD2 and hBD3 (Harder et 
al., 2001) are inducible and synthesis by epithelial cells can be stimulated by 
microorganisms and by proinflammatory cytokines e.g. TNFa and IL-1. hBD2 has been 
widely investigated and is augmented by infection in the gastrointestinal tract, 
keratinocytes, oral epithelia, respiratory tract and most other mucosal surfaces both in vitro 
and in vivo (Bajaj-Elliott et al., 2002, George et al., 2003, Harder et al., 1997, Hiratsuka et 
al., 1998, Lehmann et al., 2002, Liu et al., 1998, ONeil et al., 1999, Singh et al., 1998), 
hBD3 and -4 expression studies to date are limited.
Both defensin families reside on chromosome 8, studies by Dorin and colleagues and
McCray and co-workers have assigned the murine and human P-gene locus to 8p22-23
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region, although several newly identified p-defensins are located on chromosomes 6 and 20 
(Schutte et al., 2002, Semple et al., 2005). Sequence analyses suggest that both a and P- 
defensin families arose by gene duplication and divergent evolution (Jia et al., 2001, 
Maxwell et al., 2003, Semple et al., 2003). Defensins are encoded by two exons which 
code for a precursor pre-propeptide. This includes an N-terminal signal sequence, an 
anionic pro-segment and a C-terminal cationic segment that on cleavage yields the active 
peptide (Lehrer and Ganz, 2002). Exon 1 encodes the signal sequence and the pro and 
mature peptides are coded by the second exon. Although both neutrophil and Paneth cell a- 
defensins undergo proteolytic cleavage to yield active peptide (Eckmann, 2005), the 
processing between the two cell types is markedly different (Bajaj-Elliott, 2003). In 
neutrophils, the peptides are stored in their active form (Ganz, 1985). HD-5 and -6 are also 
synthesised as large molecules but in contrast to HNPs are stored in precursor form (Ghosh 
et al., 2002). Studies by Bevins and colleagues suggest close proximity of pro HD-5 
precursor molecule to trypsinogen in Paneth cell granules under resting conditions. Upon 
bacterial stimulation, trypsinogen is converted to trypsin, the enzyme responsible for 
converting HD-5 to its active form (Ghosh et al., 2002). Why such diverse mechanisms for 
a-defensins processing exist in nature is unknown. Sequence analyses of p-defensins shows 
the signal peptide is followed by a very short pro-piece with active molecule residing at the 
C-terminus. The short size of the pro-piece suggests that this sub-family of defensins are 
likely to be secreted directly without an intermediate storage step. However, no studies to 
date have investigated the kinetics of P-defensin peptide expression and secretion, to 
confirm the above hypothesis.
1.11.2 Protein Structure
Defensins share the general structural hallmark of AMPs i.e. they are small, (28-45 amino
acids) peptides with molecular weight ranging between 3-5kDa (Fellermann and Stange,
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2001, Niyonsaba and Ogawa, 2005). a and P-defensins differ in their disulphide linkage 
patterns; a-defensins have three intramolecular bonds positioned at C1-C6, C2-C4 and C3- 
C5, whereas p-defensins form C1-C5, C2-C4 and C3-C6 (Figure 1.8; Ganz and Lehrer, 
1998). Despite the variation in S-S linkage both peptides adapt a similar P-sheet secondary 
structure framework. The tri-disulphide folded structure is required for microbicidal 
activity of HNPs as linearised peptides are ineffective against viruses and bacteria (Daher et 
al., 1986, Mandal and Nagaraj, 2002). Interestingly, more recent data suggests that the 
primary function of the disulphide bridges is to prevent proteolysis in protease-rich effector 
sites, such as enzyme-rich environment of the GI tract (Selsted and Ouellette, 2005), as 
mutations in all three disulphide bridges in hBD3 resulted in bactericidal activity similar or 
greater than the native peptide (Wu et al., 2003). Similarly, native cryptdin-4, a mouse 
Paneth cell a-defensin, but not its disulphide bond analogs is resistant to protease 
degradation whilst none lose their antibacterial activity (Maemoto et al., 2004).
1.11.3 Mechanism of Action
Most AMPs are cationic molecules with spatially spaced hydrophobic regions. The
peptides are small (<100 amino-acids) with an excess of positive charge due to lysine and
arginine residues and are approximately 50% hydrophobic (Hancock and Scott, 2000). A
general mechanism by which the peptides are able to kill bacteria is by depolarising and
permeabilising membranes (Figure 1.9), but there are some examples in which the lethal
target is cytoplasmic (Devine and Hancock, 2002). In Gram-negative bacteria, the peptides
can associate with the negatively charged phospholipids of the outer membrane or directly
bind and replace the divalent magnesium ion binding site involved in interacting with LPS.
These modifications lead to expansion of the outer membrane causing disruption of
function and integrity. Such structural changes allow the passage of large antibiotics and
peptides themselves into the interfacial region of the inner membrane, where on reaching
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sufficient concentrations the peptides aggregate within the membrane leading to pore 
formation. Gram-positive bacteria do not have an outer membrane, but AMP binding to 
outer wall components such as lipoteichoic acid (LTA) suggests a different mode of action. 
All defensins characterised to date have direct antimicrobial activity (Ganz, 2003, Ganz and 
Lehrer, 1998, George et al., 2003, Lehrer, 2004, Lehrer and Ganz, 2002, Schroder, 1999) in 
the pM range however, there are differences in potency between the recombinant p- 
defensin peptides (George et al., 2003, Zilbauer et al., 2005). p-defensins and LL-37 (the 
only Cathelicidin family member expressed in man) show synergy against S. aureus and E. 
coli and this synergy was further enhanced in acidic conditions (Chen et al., 2005). The a- 
defensins HNP1-4, are only active at concentrations higher than 10‘5 M and exhibit broad 
range of activity, killing a range of microbes (Ganz, 2003, Yang et al., 2004).
The first molecular interaction between cationic AMP and the anionic microbial cell 
membrane is primarily electrostatic. High concentrations of salt are competitively 
inhibitory to this interaction, however, activity of hBD3 and 0-defensins is not usually 
dampened (Harder et al., 2001). The first mechanism is the formation of ion pores within 
the membrane (Figure 1.9), and the second model, “carpet model” has been suggested in 
the case of hBD2 specifically (Hoover et al., 2000). Electrostatic forces pull apart the 
peptide molecules into the membrane and the molecules accumulate in a ‘carpet’. The 
membrane is strained and the peptides shift in arrangement to relieve this strain, thereby 
forming pores or “wormholes” in the membrane (Huang, 2000, Lohner et al., 1997). 
Despite microbial membrane depolarisation and permeabilisation being the most accepted 
mechanism of defensin action, other mechanisms cannot be ruled out, such as induction of 
microbial autolytic enzymes (Sahl et al., 2005).
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Figure 1.9 The carpet-wormhole model of action of defensins. Most defensins (shown 
as large ovals) are amphipathic molecules that have clusters of positively charged amino- 
acid side chains and hydrophobic amino-acid side chains. This allows them to interact with 
microbial membranes, shown schematically with their negatively charged phospholipid 
headgroups and hydrophobic fatty acid chains (from Ganz, 2003).
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The antibacterial activity of hBD2 against H. pylori has been assessed by Hamanaka and 
colleagues as determined by co-incubation of varying concentrations of recombinant hBD2 
with the bacteria followed by plating out the test samples. hBD2 was bactericidal in the 
micromolar range with complete eradication of the organism at higher peptide 
concentrations (Hamanaka et aL, 2001). hBD3 was recently shown to be up-regulated in 
response to H. pylori infection in gastric epithelial cells (AGS) and further evaluation of the 
antimicrobial potency of hBDl-3 conducted in a similar assay revealed that hBD3 was 
most potent of the hBDs, reducing survival down to 5% in the micromolar range, followed 
by hBD2 and finally hBDl (George et al., 2003).
LL-37 has also been implicated in H  pylori infection as significant induction of this 
peptide was observed in epithelial cells and gastric secretions of H. /?y/on-infected patients 
(Hase et al., 2003). LL-37 exhibited specific anti-bacterial effects in the micromolar range. 
Induction of LL-37 was dependent upon an intact CagPAl suggesting that the secretion 
system may play a part in eliciting host antimicrobial response (Hase et al., 2003).
As multiple AMPs are likely to be present simultaneously at the mucosal surface during an 
infectious episode, synergy between the peptides may allow for more effective bactericidal 
activity against H. pylori and some synergy has been observed between the hBDs, as well 
as lysozyme or LL-37 (George et al., 2003, Hase et al., 2003). These results concur with 
those obtained in studies investigating synergistic activities of hBDs, LL-37 and lysozyme 
against E. coli and S. aureus (Chen et al., 2005). Collectively, these findings suggest a 
significant role for the hBDs, in particular the highly potent antimicrobial hBD3, in H. 
pylori- mediated disease.
1.11.4 Physiological function
In vivo physiological antimicrobial effector function for defensins has been examined by
the use of transgenic and knock-out mice. Mice lacking matrilysin, MMP-7, the enzyme
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required for converting inactive a-defensin pro-form to active peptide, were impaired in 
their ability to clear E. coli and were more susceptible to S. typhimurium infection, when 
compared to control wild type litter (Wilson et al., 1999). Salzman and colleagues observed 
increased protection of transgenic mice expressing HD-5 against Salmonella infection when 
compared to control litter, suggesting an important role for this peptide in mucosal defence 
of the GI tract (Salzman et al., 2003).
P-defensin in vivo function has also been explored. Deletion of murine P-defensin-1 gene 
(Defbl) results in defective clearance of Haemophilus influenzae from the lung (Moser et 
al., 2002). Another study showed increase in Staphylococci species in the bladders of Defbl 
K/O mice (Morrison et al., 2002). An in vivo study found increased protection from 
Bordetella pertussis infection in the presence of exogenously administrated porcine P- 
defensin (pBDl) (Elahi et al., 2006). There was also a suggestion of pBDl-mediated anti­
bacterial activity against several porcine pathogens, demonstrating p-defensins as potential 
targets for anti-pertussis therapy.
Although the bactericidal function of defensins is well-established, recent studies implicate
these peptides in novel functions including signalling to cells involved in adaptive
immunity (Oppenheim et al., 2003). Chemotactic activity of defensins occurs at nM
concentration versus pM required for antimicrobial activity. The chemotactic properties
include HNP1-3, hBD3 and -4 recruiting monocytes (Garcia et al., 2001, Garcia et al.,
2001, Territo et al., 1989), with hBD2 chemoattracting mast cells (Niyonsaba et al., 2002).
hBDl-3 are also chemotactic for immature dendritic cells (iDCs) (Yang et al., 1999,Yang
et al., 2002). Murine BD2 mediates this interaction via binding to the chemokine receptor
CCR6 present on DCs and T cells (Biragyn et al., 2002). Recent advances in
bioinformatical searches for novel p-defensin like peptides followed by in situ studies have
revealed expression of some of these peptides is limited to epithelial epididymis. It has
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been proposed that these novel members are not involved in innate defence but may serve 
physiological roles such as maturation of sperm cells of the male reproductive tract 
(Rodriguez-Jimenez et al., 2003). This would not, however, necessarily exclude any 
indirect effects on host defence. Defensins have also been implicated in epithelial and 
fibroblast cell division (Murphy et al., 1993), and enhancement of wound closure (Aarbiou 
et al., 2004).
1.11.5 Role in Health and Disease
The relationship between defensins and infectious disease pathogenesis is a topic of active 
research. Antimicrobial activity of defensins is inhibited in respiratory epithelia in cystic 
fibrosis, owing to high mucosal salt concentration, which significantly contributes to 
increased susceptibility to chronic infection (Goldman et al., 1997). The recurrent 
pulmonary infections were deduced to be due to hBDl inactivation in the presence of salt 
(Smith et al., 1996). Increased defensin levels have also been observed in other 
inflammatory lung diseases, such as diffuse panbroncheolitis (DPB), idiopathic pulmonary 
fibrosis (IPF) and acute respiratory distress syndrome (ARDS), indicating a potential role 
for defensins in the pathogenesis of these diseases, although any precise involvement still 
remains to be elucidated (Aarbiou et al., 2002).
High expression of hBD2 has been found in inflamed skin epidermal cells, whereas
keratinocytes from healthy skin do not express hBD2 mRNA expression (Liu et al., 1998).
This correlates well with high amounts of hBD2 peptide in lesional psoriatic scale extracts
(Schroder and Harder, 1999) and a corresponding decreased incidence of several types of
infection, only 7% of patients with psoriasis acquire skin infections compared to
approximately 30% with atopic dermatitis (Christophers and Henseler, 1987). This
decreased occurrence of skin infections in psoriasis has been confirmed to be due to
elevated levels of both hBD2 and LL-37 (Ong et al., 2002). So, a deficiency in expression
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of hBD2 may account for the increased susceptibility of recurrent infections for patients 
suffering from atopic dermatitis. Further investigation suggests involvement of IL-10 
dependent mechanism(s), as anti-IL-10 treatment of dermatitis skin explants enhanced the 
expression of hBD2 (Howell et al., 2005). Also, IL-4 and IL-13 have been implicated in 
suppressing TNFa and IFNy induced hBD3 induction (Nomura et al., 2003), implicating 
inflammatory processes in atopic dermatitis as important features involved in gene 
regulation.
In the gastrointestinal tract, Shigella infection leads to modulation of antimicrobial peptides 
and host defence. In both children and adults experiencing Shigella-driven diarrhoea, 
synthesis of colonic hBDl (in enterocytes) and LL-37 was noticeably suppressed (Islam et 
al., 2001). This down-regulation may be a virulence determinant in disease progression. 
Up-regulation of hBD gene and peptide expression in response to infection with another 
pathogen causing diarrhoea, C. jejuni has also been observed (Zilbauer et al., 2005). The 
mechanism(s) involved in this induction is an active area of research, as the identity of 
bacterial factors responsible for these effects remains elusive. Furthermore, several 
probiotic bacterial strains including E. coli strain Nissle 1917, cause potent induction of 
hBD-2 in intestinal epithelial cells, in an NF-KB-dependent manner (Wehkamp et al, 2004), 
confirming a role for P-defensins in intestinal innate defence.
Importantly, study into the expression of P-defensins in Inflammatory Bowel disease 
suggests increase of hBD2 and -3 in ulcerative colitis, with impaired expression in Crohn’s 
disease (Wehkamp et al, 2003). These findings implicate P-defensins in providing an 
effective mucosal barrier function in humans, suggesting disruption in Crohn’s disease is 
likely to lead to increased susceptibility to bacterial invasion, thus contributing to disease 
pathogenesis.
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The co-localisation of an intracellular peptidoglycan receptor, NOD2 and a-defensins in the 
specialised Paneth cell has led to the notion that a-defensins may contribute to the 
pathogenesis of Crohn's ilietis, a chronic Inflammatory Bowel disease (Wehkamp et al., 
2005, Bevins, 2005, Bevins, 2006, Grimm and Pavli, 2004). Interestingly, it has also been 
postulated that NOD2 mediates P-defensin expression and the promoter activity was 
severely impaired in the presence of mutated NOD2 (Voss et al., 2006), indicating a likely 
role for both defensin families in this condition.
The epithelium plays an active role in innate immune responses through the secretion of 
inflammatory cytokines, chemokines and antimicrobial peptides. One may hypothesise that 
host cell pattern recognition receptor signalling in response to microbes leads to protection 
due to induction and expression of P-defensins. These peptides may contribute to limiting 
pathogenic infection or indeed elimination of invading microorganism(s). In addition, 
defensins attract DCs and T cells leading to recruitment of adaptive immune cells.
An important issue facing the clinical management of H. pylori is the increasing prevalence 
of resistance to the antibiotic component of the present regimens. Identification of specific 
resistance mechanism(s) employed by H. pylori and our understanding of the regulation of 
naturally occurring antibiotics during infection and inflammation may provide insights into 
strategies to develop new therapeutic agents.
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Aims & Hypothesis
The hypothesis to be investigated in this thesis is that Helicobacter pylori strains that 
establish chronic mucosal infection are armed with virulence factors that directly or 
indirectly (via host inflammatory mediators) modulate expression and function of epithelial 
p-defensins. Such strains colonise the stomach more densely compared to non-virulent 
strains, resulting in increased levels of inflammation and tissue injury.
The overall aim of this project is to identify molecular mechanism(s) by which virulent H. 
pylori strains subvert the host innate immune surveillance system, allowing for its 
increased, persistent colonisation in the gastric mucosa.
The specific aims of this project are:
1. To determine the potential role of bacterial virulence factors in modulating human 
P-defensin gene expression during H. pylori infection.
2. .To delineate the signal transduction events involved in the regulation of human P- 
defensin during H. pylori infection
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CHAPTER 2 
Materials and Methods
2.0 Reagents
All cell culture reagents were purchased from Invitrogen, Paisley, UK, unless otherwise 
stated. Recombinant IL-1 p, TNFa, Epidermal growth factor (EGF) and IL-1 receptor 
antagonist (IL-1RA) were obtained from Peprotech, London, UK. The MAP Kinase 
inhibitors, SB203580, PD98059, U0126 and SP600125, the NF-kB proteasome inhibitor, 
MG132, EGFR inhibitors, AG1478 and PD168393, and JAK inhibitor I were from 
Calbiochem, Nottingham, UK. Non phospho- and phospho-specific antibodies for MAP 
Kinases (p44/42, p38, SAPK/JNK), phospho-NF-KB p65 (Ser 536), NF-kB inhibitory 
protein (IicBa and IkBP) antibodies were attained from Cell Signalling Technology, 
Hitchin, Hertfordshire, UK and Autogen Bioclear, Wilts, UK respectively. Neutralising 
EGFR and human p-defensin 2 antibodies were from Autogen Bioclear, Wilts, UK and 
human P-defensin 3 antibody was from Gentaur Molecular Products, Brussels, Belgium, p- 
actin antibody was from Sigma, Poole, UK.
2.1 Human epithelial cell-lines
The human gastric epithelial cell line AGS was used throughout the study. This cell-line 
was maintained in RPMI 1640 culture medium with 2mM L-glutamine supplemented with 
10% heat inactivated fetal calf serum (FCS; Sigma, Poole, UK), 100 units/ml penicillin, 
lOOpg/ml streptomycin, and 1% non-essential amino acids. This media is referred to as 
complete media hereafter.
Human embryonic kidney cell-line (HEK 293) used for transfection experiments was 
grown in Minimal Essential media (MEM) with 10% heat inactivated FCS, 2mM L- 
glutamine, 100 units/ml penicillin, lOOpg/ml streptomycin, 1% non-essential amino acids, 
and 20mM Hepes buffer (pH 12-1.5).
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Stably transfected HEK293 cells expressing conditional kinase AMEKK3:ER* (HM3 cells) 
(Todd et al., 2004) and conditional ARaf-l:ER* (HR1 cells; kindly provided by Dr Simon 
Cook, Babraham Institute, Cambridge, UK) were maintained in phenol red-free DMEM 
high-glucose medium containing lOOpg/ml penicillin-streptomycin, 2mM L-glutamine, 
10% FCS, 400 pg/ml geneticin or 2pg/ml puromycin (Sigma, Poole, UK). The cells were 
kept at 37°C and 5% CO2 in a humidified incubator (Galaxy CO2 Incubator, Wolf 
Laboratories, UK).
2.1.1 Cell Passage
Confluent cell-line monolayers were routinely passaged by trypsinisation when appropriate. 
Cells were washed twice with sterile phosphate buffered saline (PBS) before adding lx 
Trypsin-EDTA to cover the cell surface for 5 minutes at 37°C. This allowed adherent cells 
to detach and trypsin activity was immediately inhibited by the addition of complete media 
containing 10% FCS. The resultant cell suspension was centrifuged (lOOOrpm, 10 min, 
4°C) (Rotina 46R centrifuge, Wolf Laboratories, UK) followed by resuspension of the cell 
pellet in complete media prior to centrifugation to minimise any remaining trypsin activity. 
Cells were seeded and maintained in 25cm2 or 75cm2 culture flasks, 6 or 96 well plates 
(Coming Life Sciences, UK) at a concentration as required.
2.1.2 Counting viable cells
lOpl of the cell suspension was added to lOpl of 0.4% trypan blue (Sigma, Poole, UK) for 
lmin. lOpl of this mixture was placed onto a haemocytometer counting chamber (BDH 
Laboratories, Poole, UK), and live cells counted under a microscope (Zeiss, Germany) at a 
magnification of x 40. The unstained viable cell count was:
The number of cells within a 25 box field x dilution factor = Total number of cells x 104 
/ml
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2.1.3 Freezing cells
For long term storage, confluent adherent cell-lines were washed twice with sterile PBS and 
trypsinised as described above. AGS cells were centrifuged (lOOOrpm, lOmin, 4°C) and 
resuspended in 80% FCS, 10% complete media and 10% sterile dimethyl sulphoxide 
(DMSO; Sigma, Poole, UK). HEK 293 cells were resuspended in 90% FCS and 10% sterile 
glycerol (Sigma, Poole, UK). 1ml cell suspension aliquots were transferred into cryovials 
(Nunc, Roskilde, Denmark) and slowly chilled to and stored at -80°C or liquid nitrogen 
(New Brunswick Scientific, Jencons PLC, UK).
2.1.4 Thawing ceils from -80°C storage
Cryovials were removed from storage and placed immediately into a water bath at 37°C to 
permit rapid thawing. Thawed cells were added to complete media previously warmed to 
37°C and centrifuged (lOOOrpm, lOmin, 4°C) to remove DMSO/ glycerol. The cell pellet 
was resuspended in complete media, before proceeding with culturing in a 25cm tissue 
culture flask.
2.2 Bacterial culture
2.2.1 Preparation of blood agar plates
Bacterial reagents for maintaining Helicobacter pylori strains including horse blood, agar 
and selective supplements were purchased from Oxoid, Basingstoke, UK.
Wild type Helicobacter pylori strains were grown on blood agar plates prepared using 
autoclaved Columbia Agar Base, supplemented with 5% horse blood and Helicobacter 
pylori selective (Dent) supplement. H. pylori selective supplements comprised: 
Vancomycin (5mg); Cefsulodin (2.5mg); Trimethoprim lactate (2.5mg) and Amphotericin 
B (2.5mg). Aseptically 2ml of sterile PBS was added to one vial of selective supplement
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and mixed gently to dissolve. The contents were then added to 500ml of Columbia Blood 
Agar Base cooled to 50-55°C and mixed well before pouring into sterile Petri dishes.
2.2.2 Helicobacter pylori strains
Helicobacter pylori strains used throughout the study were kind gifts from Professor John 
Atherton (Institute of Infections, Immunity and Inflammation, Queens Medical Centre, 
Nottingham, UK) and Dr Andrew Harris (Institute for Cell and Molecular Sciences, Queen 
Mary College, London, UK) and stored in glycerol at -80°C (Table 2.1). Bacteria were 
grown on blood agar plates and maintained under microaerophilic conditions with 
CampyGen sachets, in aerojars incubated at 37°C. A sterile bacterial loop was utilised to 
streak bacteria onto a blood agar plate. Isogenic mutants were grown in the presence of 
kanamycin (50pg/ml; Sigma, Poole, UK) on blood agar plates.
2.3 Co-culture studies
2.3.1 Gastric epithelial cells with Helicobacter pylori
After media removal, AGS cells were washed twice with PBS and incubated overnight in 
low (0.5%) serum media prior to addition of bacteria. Cells were routinely maintained in 
0.5% FCS media without antibiotics during bacterial-epithelial co-culture experiments. A 
multiplicity of infection (MOI) of 100 [i.e., lxlO6 epithelial cells/ 1x10s bacteria] was 
employed (Bajaj-Elliott et al, 2002). Bacteria were counted firstly by resuspending 
colonies in PBS using sterile techniques and quantified by measuring optical density at 
450nm (6300 Spectrophotometer, Jenway, UK).
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Helicobacter pylori strain Characterisation
HP 60190 Cytotoxic Wild Type wacA slm l, cag positive
HP 60190 : : cagA Isogenic mutant, cagA deleted
HP 60190 :: cagE Isogenic mutant, cagE deleted
HP 60190 :: vacA Isogenic mutant, vacA deleted
HP 84183 Cytotoxic Wild Type vacA slm l, cag positive
HP 84183 ::cagA Isogenic mutant, cagA deleted
HP 84183 v.cagE Isogenic mutant, cagE deleted
HP 84183 :: vac A Isogenic mutant, vacA deleted
HP 26695 Cytotoxic Wild Type
HP J150 Non-cytotoxic strain, vacA s2m2, cag positive
HP J99 Cytotoxic Genome strain vacA, slm l, cag positive
HP Tx30a Clinical isolate, cag PAI negative
Table 2.1 Helicobacter pylori strains, clinical isolates and isogenic mutants utilised in 
the present study.
Bacterial counts were obtained as follows:
OD at 450nm x dilution factor = 1 x 108 colony forming units per ml (cfu/ml).
The bacterial suspension was appropriately diluted to a final concentration of lx l08/ml and 
added directly to epithelial cell cultures. Visualisation of cell vacuolation 6-8h post­
infection was an indicator of infection.
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2.3.2 Epithelial cell stimulation
Cytokine and 4-Hydroxytamoxifen (4-HT; Sigma, Poole, UK) stimulation studies were 
undertaken in low serum media in the presence of antibiotics. All recombinant cytokines 
and agonists were reconstituted according to manufacturer’s instructions. The following 
concentrations were used in the present study: Interleukin-1(3 (IL-ip) 20ng/ml; Tumour 
necrosis factor- a (TNF-a) 20ng/ml; Interferon-y (IFN-y) 40ng/ml (approximately 
lOOU/ml); Interleukin-1 receptor antagonist (IL-1RA) 200ng/ml; 4-Hydroxytamoxifen (4- 
HT) 100 nM; Recombinant Epidermal Growth Factor (EGF) 50ng/ml. The concentrations 
utilised are known to have minimal cytotoxic effects on epithelial cells.
2.3.3 Inhibitor studies
All inhibitors were reconstituted and prepared to the relevant stock concentrations 
according to the manufacturer’s instructions. The concentration of inhibitors for specific 
signal transduction pathways were as follows: p38 inhibitor SB203580, 25pM; ERK 
inhibitor PD98059, 25pM; ERK inhibitor U0126, 25^M; JNK inhibitor SP100625, 50pM; 
NF-kB inhibitor MG132, 25pM; EGFR inhibitor AG1478, 3pM; EGFR inhibitor 
PD168393, 2pM; JAK Inhibitor I, 540nM; EGFR neutralising antibody, lOpg/ml. 
Routinely, cells were pretreated with inhibitors for 30-60min prior to proceeding with 
cytokine/ bacterial co-stimulation studies. The presence of the inhibitors was maintained 
throughout the course of each experiment.
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2.4 Gene expression of host defence genes by Reverse Transcription- Polymerase 
Chain Reaction (RT-PCR)
2.4.1 Total RNA isolation
Reagents for RNA extraction, RT and PCR analyses were from Invitrogen, Paisley, UK 
unless otherwise stated. Cells were washed twice with PBS and stored at -80°C until 
required. Total RNA isolation was carried out using a monophasic solution of phenol and 
guanidine thiocyanate (TRIZOL), of which 1ml was added directly to a 25cm flask or 1 
well of a 6 well plate. The cell layer was gently shaken (Rotatest, Denley, UK) for lOmin at 
room temperature to allow complete suspension of cells. The viscous solution (due to 
cellular DNA) was transferred into a sterile 1.5ml eppendorf. Vigorous repeated dispersion 
of the solution through a needle and syringe (25gauge, Terumo, Leuven, Belgium) allowed 
further homogenisation. The resultant Trizol solution was allowed to stand at room 
temperature for 5min to permit greater dissociation between nucleic acid-protein 
complexes. 200pi chloroform (Sigma, Poole, UK) was added per ml Trizol used and 
vortexed thoroughly (Vortex Genie-2, Scientific Industries, NY, USA) for 15sec before 
centrifugation (13000rpm, 20min, 4°C) (Eppendorf 5415R microfuge, Eppendorf, 
Cambridge, UK). This procedure allowed organic extraction of the total RNA from the 
remaining cellular debris. The resultant top aqueous layer (comprising RNA) was aspirated 
(approximately 500pl) and transferred into a fresh eppendorf. RNA was precipitated by the 
addition of 500pl isopropanol (Sigma, Poole, UK). Extracted RNA was stored at -80°C.
2.4.2 Spectrophotometric quantification of total RNA
Total RNA was pelleted by centrifugation (13000rpm, 20min, 4°C) and washed with ice- 
cold 70% ethanol (BDH Laboratories, Poole, UK). The RNA pellet was either vacuum 
(Heto Vacuum Centrifuge, Jencons PLC, UK) or air-dried to remove traces of ethanol prior
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to the addition of RNase- free water (Sigma, Poole, UK). Appropriate amounts of 
resuspended RNA solution were diluted in water and concentration determined by 
absorbance (U-1800 Spectrophotometer, Digilab Hitachi, Tokyo, Japan) at 260nm and 
280nm. The amount of RNA (pg/pl) was calculated as follows: [(reading at 260nm) x 
(dilution factor) x 40] / 1000.
Typically, 1 x 106 cells would yield approximately 20-25 pg.
2.4.3 Reverse transcription (RT)
5pg of total cellular RNA was transcribed to complementary DNA (cDNA) using Moloney 
murine leukaemia virus reverse transcriptase. In a typical RT reaction, lpl (0.5 pg) oligo-dT 
was added to 5pg of RNA and heated to 70°C for lOmin followed by immediate chilling on 
ice to permit greater specific annealing between oligo-dT and poly-A tail of mRNA 
molecules.
The remaining components of the reaction: 5 x First strand buffer, 4pl; 0.1M DTT, 2pl; 
lOmM deoxynucleotide triphosphates (dNTP) mix, 1 pi; 100U Enzyme (reverse 
transcriptase), 0.5pl; were then added and the reaction allowed to proceed at 42°C for lh. 
The reaction was terminated by heat inactivated at 70°C for lOmin.
2.4.4 Polymerase Chain Reaction (PCR)
cDNA obtained was used in subsequent PCR reactions. Reaction volumes were 25pl, of 
which 12.5pl of 2x PCR master mix (Biomix Red, Bioline Ltd, London, UK) encompassed 
PCR buffer, 1.5 mM MgCE, 200 pM dNTPs and Taq polymerase. In addition, 2pl of 20 
pmol of each oligonucleotide primer and 2pl cDNA were included to complete the reaction 
mix. Primers utilised are listed in Table 2.2. The remainder consisted of RNase free water 
to total 25pl. Master mixes were prepared for multiple reactions to minimise inter-sample 
variation. Contents of the PCR reaction (Abgene, Epsom, Surrey, UK) were mixed by brief
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> - - 32-37 cycles
centrifugation. PCR amplification was carried out in a thermal cycler (Peltier Thermal 
Cycler, DNA Engine Systems) as follows:
a) 94°C for 3min to denature the template - 1 cycle
b) 94°C denaturation for 90 sec 
58°C annealing for 90 sec 
72°C extension for 90 sec
c) 72°Cforl0min -1 cycle
Finally, PCR products were quantified by agarose gel electrophoresis (Flowgen, 
Nottingham, UK). 2% agarose (Invitrogen, Life Technologies, Paisley, UK) gels were
prepared in 1 x Tris borate EDTA (TBE) buffer (National Diagnostics, UK) and bands
visualised by ethidium bromide (Sigma, Poole, UK) staining. Semi-quantitative analyses 
were conducted by densitometric measurements of bands followed by normalisation to the 
house-keeping gene, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Alpha Imager, 
Multimage Light Cabinet, Alpha Innotech Corporation, Essex, UK).
Target gene Sense primer Anti-sense primer Product size (bp)
hBDl luvTTG TCT GAG ATG 
GCC TCA GGT GGT 
AAC136
3“ ATA CTT CAA AAG CAA 
TTT TCC TTT AT337
253
hBD2 "CCA GCC ATC AGC 
CAT GAG GGT CTT34
2S'CAT g t c  g c a  c g t  c tc
TGA TGA GGG AGC261
276
hBD3 2taGGT GAA GCC TAG 
CAG CTA TGA GGA TC227
3“ GAG CAC TTG CCG ATC 
TGT TCC TCC362
183
IL-8 4iATG ACT t c c  a a g  c t g  
GCC GTG62
JJ"TCT CAG CCC TCT TCA 
AAA ACT TCT C308
291
NODI W4ATT CTG g a c  CTG 
GTA CAG AGC655
™CAG GAT GAA GAT GGT 
CTC ACC977
364
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COX2 4/7CCT TCT CTA ACC TCT 
CCT ATT ATA CTA G504
s/5AGA TCA TCT CTG CCT 
GAG TAT CTT855
401
IL-18 " 9GCT GCT GAA CCA 
GTA GAA GAC AAT 
TGC225
38JCCT TGATGT TAT CAG 
GAGGAT TC561
464
Lysozyme l0sGAA CTC TGA AAA 
GAT TGG GAA TGG A132
463ACA ACC TTG AAC ATA 
CTG ACG GAC A439
355
GAPDH 630c t a  CTG g c g  CTG 
GCA AGG CTG T651
959GCC ATG AGG TCC ACC 
ACC CTG CTG966
358
Table 2.2 Sequences of synthetic oligonucleotide primers used to study innate host 
defence gene expression.
2.5 Western Blotting
2.5.1 Detection of signal transduction components
Equipment and reagents for Western blotting were from Bio-Rad Laboratories, Hemel 
Hempstead, UK and Amersham Biosciences, St Albans, UK. All buffer recipes are detailed 
in Table 2.3. Experiments were routinely set up in 25cm2 flasks or 6 well tissue culture 
plates, at the end of which media was aspirated, cells washed twice with PBS prior to lysis 
in 250pl 2x Laemmli sample buffer. Cell lysates were agitated on a rotary shaker (Rotatest 
shaker, Denley, UK) to obtain a cell suspension which was transferred into 1.5ml 
eppendorf, and homogenised by shearing and sonication (Bandelin Sonopuls, Bandelin 
Electronics, Berlin, Germany) for 10-15sec on a power setting of approximately 60%. 
Samples were boiled at 95-100°C for 5min and cooled on ice before being micro­
centrifuged for a further 5min. Supernatants were then subjected to 7-10% SDS 
polyacrylamide gel electrophoresis (SDS-PAGE) in a Mini-Protean 3 cell unit (Sambrook 
and Russell, 2001). 5pi of ColorBurst prestained Electrophoresis markers (Sigma, Poole, 
UK) was run for molecular weight determination and a visual check for transfer efficiency.
Typically, lOpl of sample was loaded into each well and run at a voltage of 100V for an 
appropriate length of time. Proteins were transferred onto nitrocellulose membrane by semi­
dry blotting (12V for 45min) using Transfer blot, Semi-dry transfer cell. Prior to transfer, 
blotting paper (VWR, Lutterworth, UK), nitrocellulose membrane (Hybond ECL) and the 
SDS-PAGE gel were allowed to equilibrate in chilled transfer buffer for at least 5min. After 
transfer non-specific binding was blocked by incubating the membrane in blocking buffer 
for l-2h at room temperature with gentle shaking. This was followed by overnight 
incubation with phospho-specific primary antibody (see Table 2.4) in blocking buffer on a 
suspension mixer at 4°C.
Tris-Glycine Tris-Tricine
SDS Sample buffer (4x) 1ml Tris (0.5M, pH 6.8), 
0.8ml Glycerol, 1.6ml 10% 
SDS, 0.4ml p-mercaptoethanol, 
0.2% Bromophenol blue, 3.8ml 
Deionised water
(lx) 200mM Tris-HCl (pH 
6.8), 40% glycerol, 2% SDS, 
0.04% Coomassie Blue
Electrophoresis Buffer 
pH 8.3
25mM Tris, 192mM Glycine, 
0.1% SDS
lOOmM Tris, lOOmM 
Tricine, 0.1% SDS
Transfer Buffer 25 mM Tris, 0.2 M Glycine, 
20% Methanol
lOOmM Tris, lOOmM 
Tricine
Blocking buffer 1 x TBS/0.1 % Tween-20, 5% 
w/v nonfat dry milk (Marvel)
1 x TBS/0.1 % Tween-20, 
5% w/v nonfat dry milk 
(Marvel)
Table 2.3 Buffer composition for Tris-Glycine and Tris-Tricine SDS PAGE. All 
reagents were purchased from Sigma or BDH Laboratories, Poole, UK.
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Primary Antibody Source Dilution Company
Phospho p44/42 MAP 
Kinase (Thr202/Tyr204)
Rabbit polyclonal IgG 1:1000 Cell Signalling Technology
P44/42 MAP Kinase Rabbit polyclonal IgG 1:1000 Cell Signalling Technology
Phospho p38 Map Kinase 
(Thrl80/Tyrl82)
Rabbit polyclonal IgG 1:1000 Cell Signalling Technology
P38 Map Kinase Rabbit polyclonal IgG 1:1000 Cell Signalling Technology
Phospho SAPK/JNK Map 
Kinase (Thrl83/Tyrl85)
Rabbit polyclonal IgG 1:1000 Cell Signalling Technology
SAPK/JNK Map Kinase Rabbit polyclonal IgG 1:1000 Cell Signalling Technology
Phospho NF-kB p65 
(Ser536)
Rabbit polyclonal IgG 1:1000 Cell Signalling Technology
NF-kB p65 Goat polyclonal IgG 1:250 Santa Cruz Biotechnology
IkB-cx Rabbit polyclonal IgG 1:1000 Cell Signalling Technology
IkB|3 Rabbit polyclonal IgG 1:250 Santa Cruz Biotechnology
|3-actin Mouse monoclonal IgGl 1:2000 Sigma
hBD2 Goat polyclonal IgG 1:500 Autogen Bioclear
hBD3 Rabbit polyclonal IgG 1:1000 Gentaur Molecular Products
Phospho-tyrosine Mouse polyclonal IgG 1:10000
Epidermal Growth Factor Mouse polyclonal IgG 1:1000
Secondary Antibody
Anti-mouse antibody 
conjugated to horseradish 
peroxidase
Sheep anti-mouse IgG 1:2000 Amersham Biosciences
Anti-rabbit antibody 
conjugated to horseradish 
peroxidase
Goat anti-rabbit IgG 1:2000 Cell Signalling Technology
Anti-goat antibody 
conjugated to horseradish 
peroxidase
Rabbit anti-goat IgG 1:2000 Dakocytomation Ltd
Table 2.4 Antibodies utilised in the present study.
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After 3-4 washes in Tris- buffered saline with 0.1% Tween-20 (TBS/T; Sigma, Poole, UK) 
for lOmin each, the blot was incubated in relevant secondary antibody for lh on the rotary 
shaker at RT. Blots were washed 3-4 times for lOmin with TBS/T before being exposed to 
an enhanced chemiluminescence (ECL) reaction for 5min, where 1ml of reagent A was 
added to 25pl of reagent B (ECL plus, Amersham Biosciences, UK). The excess solution 
was drained and membrane placed between a sheet of clingfilm prior to development. The 
membrane was exposed to an x-ray film (Hyperfilm ECL) ranging from 30sec to 15min and 
developed. To ensure equal protein loading, the same membrane was stripped in lx 
stripping solution (Re-blot plus mild solution, Chemicon, UK) for 20min, blocked in 
blocking buffer, for l-2h with gentle agitation and re-probed with a monoclonal anti-P-actin 
antibody or the corresponding non-phospho specific antibody.
2.5.2 Human p-defensin Peptide detection
Both uninfected control, infected supernatants and cell lysates were subjected to detection 
for P-defensin peptides; hBD2 and hBD3. Protein was quantified by BCA assay (Sigma, 
Poole, UK) as described below. Tris-Tricine loading buffer (Bio-Rad Laboratories, Hemel 
Hampstead, UK) was added directly to 150pg of total protein prior to the mixture being 
subjected to 16% Tris-Tricine sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
(SDS-PAGE; Table 2.5). Tris-tricine markers (Bio-Rad Laboratories, Hemel Hempstead, 
UK) were loaded alongside samples, as were recombinant peptides (hBD2 is 4.3kDa and 
hBD3 is 5.1kDa). After electrophoresis, gels were transferred onto a polyvinylidene 
difluoride (PVDF) membrane at 0.8mA/cm2 for 40min. The membrane was exposed to UV 
cross-linking (auto-crosslink setting) followed by blocking in 5% non-fat milk/TBS for lh. 
The blots were incubated in 1:500 dilution for hBD2 and 1:1,000 for hBD3 overnight, 
followed by three washes with TBST prior to incubation with horseradish peroxidase-
conjugated rabbit anti-goat IgG and goat anti-rabbit IgG (1:1,000; Dako Ltd., High 
Wycombe, UK), respectively. The reaction was developed by ECL as stated above.
Components for 16% Resolving gel Component Volume (~30ml) 1 large gel
Water 5.97
Glycerol 4g (= 3.17ml)
30% Acrylamide mix (Protogel, National 
Diagnostics, UK)
10.86
3 M Tris-Cl (pH 8.45) 10.0
10% SDS 0.3
10% Ammonium persulphate 0.05
TEMED 0.015
5% Stacking gel Component Volume (~20ml) for 2 gels
Water 10.0
30% Acrylamide mix 3.4
3 M Tris-Cl (pH 8.45) 6.2
10% SDS 0.2
10% Ammonium persulphate 0.05
TEMED 0.025
Table 2.5 Composition of Tris-Tricine SDS- Polyacrylamide Gels.
2.5.3 Protein Determination
Protein levels were determined using a Bicinchoninic Acid (BCA) Protein Assay Kit
(Sigma, Poole, UK). The principle is similar to the Lowry procedure; both rely on the
formation of a Cu2+ protein complex under alkaline conditions, followed by reduction of
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Cu2+ to Cu1+ which is monitored by the production of a purple-blue complex (Smith, 1985). 
The amount of reduction is proportionate to protein concentration. The BCA working 
reagent was prepared by mixing 50 parts of Reagent A (Bicinchoninic acid) with 1 part of 
Reagent B (Copper sulphate). 20 parts of the BCA working reagent was then mixed with 1 
part of protein sample. A blank with buffer alone, Bovine Serum Albumin (BSA) standards 
of varying concentrations (2pg to 25 pg) were also included. BCA was added to each protein 
sample, vortexed gently and left at 37°C for 30min. The solutions were transferred into 
cuvettes and OD readings taken at 562nm. Protein concentration in samples was determined 
using the standard curve plotted for BSA.
2.6 Transformation of Plasmid DNA into Competent E.coli cells
Renilla, IL-8, A46R and A52R plasmids were generous gifts from Dr Andrew Bowie 
(Trinity College, Dublin, Ireland). NODI and NOD2 siRNA plasmids were kindly 
provided by Dr Barbara Manzo (Queen Mary School of Medicine and Dentistry, London, 
UK). Luciferase reporter constructs of hBD2 and hBD3 were kind gifts from Mr Shao-ren 
Wang (Institute of Child Health, London, UK) and Dr Ole Sorensen (Lund University, 
Lund, Sweden) respectively.
Plasmid DNA received was first transformed in JM109 competent cells (Promega,
Southampton, UK). The procedure involved thawing out competent cells on ice and DNA
(l-10ng) was added by gentle flicking to 50pl of thawed cells and left for 30min on ice.
Cells/DNA complex were heat-shocked for 2min at 42°C and immediately placed on ice for
a further 5min. 1ml LB (Luria Bertani) broth (Merck, Hoddesdon, Hertfordshire, UK)
containing lOmM Mg2+ and lOmM D-glucose was added to each transformation reaction,
which was further incubated for an hour at 37°C with gentle shaking. Ampicillin
(lOOpg/ml) plates were prepared with LB agar and various dilutions of the transformation
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reaction were plated and incubated overnight at 37°C. The following day colonies were 
appropriately analysed.
2.7 Purification of Plasmid DNA
Plasmid DNA was purified using Qiagen Maxi-prep kits based on a modified alkaline lysis 
procedure, according to the manufacturer’s instructions (Crawley, West Sussex, UK). 
Briefly, a single colony was used to inoculate a starter culture of 5ml LB broth (ampicillin 
100pg/ml) in a sterile 50ml falcon tube and incubated for a few hours at 37°C with 
vigorous shaking (300rpm). The starter culture was diluted further (1 in 50) and shaken 
overnight at 37°C for a large scale plasmid preparation.
Bacterial cells were harvested 16h later by centrifugation (6000rpm, 15min, 4°C) (Sorvall 
GSA rotor, Hertfordshire, UK). Bacterial pellet was resuspended in 10ml Buffer PI, Buffer 
P2 was added and mixed by inversion several times and incubated at room temperature for 
5min. 10ml chilled Buffer P3 was then added and mixed by inversion before being left on 
ice for 20min. The latter step allows precipitation of proteins and chromosomal DNA from 
the lysed bacterial cell suspension.
The precipitated cellular debris was removed by centrifugation (13,000rpm, 30min, 4°C).
The resultant supernatant containing plasmid DNA was removed and centrifugation
repeated for 15min. The supernatant was further purified using the Qiagen-tip column. The
column was equilibrated in Buffer QBT prior to usage. Once the supernatant was applied,
the column was washed twice with 30ml Buffer QC following elution of the plasmid DNA
with 15ml Buffer QF. Plasmid DNA was precipitated by the addition of 0.7 volumes
isopropanol and centrifuged promptly at 13,000rpm for lOmin. The resultant DNA pellet
was allowed to air-dry for lOmin before the addition of TE buffer, pH 8. An aliquot was
run on a 1% agarose gel for determination of yield and purity which was verified by
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spectrophotometry: DNA (pg/pl) was calculated as follows: [(reading at 260nm) x (dilution 
factor) x 50] / 1000). Plasmid DNA was stored in aliquots at -20°C until required or stored 
long term as bacterial glycerol stocks.
2.8 Transient transfection of epithelial cell-lines
HEK 293 and AGS cells were plated in a 96-well plate at a density of 2 x 104 cells /well in 
200pl complete media. Transfections were conducted the following day using FuGene 
reagent (Roche, Lewes, UK) as recommended. All experiments were performed at a cell 
confluency of 50-80% with FuGene transfection reagent (pi) to DNA (pg) ratio of 4:1. 
Each transfection comprised a total DNA content of 230ng. This included:
a) Test plasmid i.e. Firefly luciferase constructs under investigation, IL-8, hBD2 or 
hBD3 promoter.
b) HSV TK Renilla luciferase construct, to correct for transfection efficiency
c) Empty vector (pcDNA3.1; Stratagene, Cambridge, UK) to make up the appropriate 
amount of DNA for each experiment.
d) Additional signalling pathway plasmids A46R, A52R (Vaccinia Virus proteins), 
siNODl or siNOD2.
20ng of Renilla control plasmid was co-transfected with each experimental plasmid (60ng)
and 150ng of empty vector was also included to give the final concentration of 230ng. Each
experimental condition was performed in triplicate (Bowie et al., 2000).
A master mix of transfection reagent in Optimem low serum media (Invitrogen, Paisley,
UK) was prepared. 0.8pi of FuGene was added to 9.2pl Optimem low for each individual
well. A negative control (empty vector alone and no DNA) was also included. The DNA
mix and FuGene/Optimem were incubated for a minimum of 20min at room temperature to
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allow DNA-FuGene complex formation, before being added to cells. Transfections were 
allowed to proceed for 24h prior to cytokine or bacterial stimulation. At the end of each 
experiment, cells were harvested by removing media followed by washing with ice-cold 
PBS. 50jnl of 1 x passive lysis buffer (Promega, Southampton, UK) was added to each well. 
Plates were stored at -20°C until analysis, at which stage 25 pi cell lysate was transferred 
into 2 white luciferase assay plates (Labtech International, Ringmer, East Sussex, UK). One 
plate was used for the analysis of Renilla luciferase activity, where 40pl of its substrate, 
Coelentrazine (2pg/ml; Insight Technologies, London, UK) was added to each well. lOOpl 
firefly luciferase substrate (Promega, Southampton, UK) was added to each well in the 
other plate for the detection of luciferase activation. IL-lp (20ng/ml), a potent agonist for 
IL-8 and hBD2 gene expression was included as a positive control in all experiments. 
Reporter gene activity was quantified using a 96 well plate luminometer (LUCY1 
luminometer, Anthos Labtech Instruments, Austria). All experiments were conducted at 
least twice and performed in triplicate. Luciferase activities were plotted as fold induction 
compared to activity measured in unstimulated control cells.
2.9 Short Interfering RNA (siRNA) experiments
Plasmids encoding NODI and NOD2 (Dr Barbara Manzo, Queen Mary School of Medicine 
and Dentistry, London) or commercially available double-stranded NODI siRNA (Cat #: 
16708; Ambion Europe Ltd, Huntingdon, UK) were utilised in this series of experiments. 
NODI or NOD2 siRNA plasmid (lOOng/well) was introduced to cells with empty vector 
pcDNA3.1 (total DNA concentration 230ng/well) using FuGene transfection reagent 24h 
prior to transfection with test plasmids as described above.
A second strategy targeting endogenous NODI (sequence; sense: GGC CAA AGU CUA 
UGA AGA Utt anti-sense: AUC UUC AUA GAC UUU GGC Ctc) was carried out utilising
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a reverse transfection method. Cells were trypsinised, washed and resuspended to a 
concentration of 1 x 104 cells/ml. 25nM and 50nM commercially available dsRNA NODI 
siRNA was added to Optimem media (lOpl/well). Transfection reagent specific for reverse 
transfection, siPort NeoFX™, (0.5 p 1/well; Ambion Europe Ltd, Huntingdon, UK) was 
added to Optimem media (lOpl/well) and combined to the siRNA-Optimem mix. The 
mixture was left for 20min at room temperature and 20pl added to each well of a 96 well 
culture plate followed by addition of 80pl cell suspension. Media was replaced 24h after 
transfection and p-defensin promoter constructs were introduced via FuGene transfection 
method as described above 48h after initial transfection of siRNA. All subsequent steps 
were carried out as described for transfection of luciferase- promoter constructs.
2.10 Statistics
Results are presented as means ± SEM of three experiments each performed in triplicate. 
Statistical analyses were performed using SPSS and GraphPad Instat statistical software, 
variables were compared using a T-test and a probability value of less than 0.05 was 
regarded as significant.
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CHAPTER 3 
Role of H. pylori Virulence Factors in 
mediating p-defensin Expression
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3.0 Background
Epithelial cells represent a first line of defence between host and the environment. Not only 
does the epithelium protect by presenting a physical barrier against pathogens but also 
through mounting innate immune response(s) including the induction of chemokines (e.g. 
IL-8) and antimicrobial peptides such as p-defensins (Bajaj-Elliott et al., 2002, Crabtree et 
al., 1993, Keates et al., 1997, O'Neil et al., 2000). Most studies to date have been confined 
to studying effect of cytotoxic H. pylori strains on hBD2 expression (Bajaj-Elliott et al., 
2002, George et al., 2003, Hamanaka et al., 2001, O'Neil et al., 2000, Wada et al., 1999, 
Wada et al., 2001), although Wada and colleagues looked at the contribution of CagPAI, at 
present, the potential role of bacterial virulence factors in mediating p-defensin expression 
is unknown.
In order to address the potential contribution of H. pylori virulence determinants in 
mediating P-defensin expression, several isogenic mutant strains including cagA-ve strain 
(lacking the bacterial effector protein), cagE-ve strain (lacking a component of the type IV 
secretion system rendering it dysfunctional), vacA-ve strain (lacking the secreted exotoxin 
which causes vacuolation of host cells) and finally cagPAI-ve strain (deficient in the whole 
syringe system) were utilised.
3.1 p-defensin expression in response to H. pylori
Firstly the effect of epithelial cell infection with wild type cytotoxic H. pylori strains 
(vacA+ve and cag+ve) was assessed. hBDl expression was found in control uninfected 
cells and this constitutive expression was observed throughout the infection (Figure 3.1; 
lanes A, D and E). In contrast, the expression of two other members of the family hBD2 
and -3 was inducible (Figure 3.1; lane D, E). Although, hBD2 has been demonstrated by
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hBDl
hBD2
hBD3
GAPDH
Figure 3.1: Expression of p- defensins during H. pylori infection. hBDl mRNA is 
constitutively expressed by gastric epithelial cells, whereas hBD2 and 3 are both induced 
by IL-ip and H. pylori 8h post-stimulation. Lane A shows control unstimulated cells, Lane 
B and C represent cells stimulated with IL-lp and TNFa (both at 20ng/ml concentration) 
respectively. Cells also expressed p-defensins upon treatment with two cytotoxic wild type
o
H. pylori strains (1x10 cfu/ml Hp 60190, 84-183) as seen in Lane D and E. Results shown 
are representative data from three experiments.
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several studies, this is the first study showing induction of hBD3 gene expression by H. 
pylori, this data has now been reported (George et al., 2003). Binding of IL-ip to its 
receptor is known to trigger signal transduction events resulting in activation of NF-kB in 
many cell types (Dunne and O'Neill, 2003). As NF-KB-mediated hBD2 expression is a 
defined pathway for hBD2 gene regulation in various models of infection and inflammation 
(Harder et al., 2000, Krisanaprakomkit et al., 2000, Liu et al., 2003, O'Neil et al., 1999), 
IL-lp was the agonist of choice as a positive control throughout the study.
The role of two critical innate immune genes IL-8, a potent neutrophil-activating 
chemokine and cyclooxygenase-2 (COX-2), an enzyme involved in the pathogenesis of 
gastric inflammation and carcinoma, is well established (Crabtree, 2001, Juttner, 2003). As 
the extent and degree of infection was most likely to vary between individual experiments, 
the expression of IL-8 and Cox-2 was also assessed as a marker of infection. The kinetics 
of IL-8, Cox-2 and P-defensin gene expression was followed by time-course studies both 
during bacterial infection and cytokine stimulation (Figure 3.2). Expression of hBD2 was 
rapid with maximal induction observed 6h post-infection (Figure 3.2a; uppermost panel) 
and declined slowly thereafter. Similar kinetics of hBD2 gene expression were also 
observed in the presence of IL-lp (Figure 3.2b; uppermost panel). In contrast to hBD2, 
induction of hBD3 was slow, reaching maximal levels between 12-24h (Figure 3.2; second 
panel). Interestingly, hBD2 expression was consistently more potently induced in response 
to IL-lp stimulation compared to H. pylori, whereas there was not such a difference noted 
for IL-8 or hBD3 expression exposed to the different stimuli. Both IL-8 and Cox-2 
expression was found to be constitutive in unstimulated AGS cells and further induction 
was observed in particular when exposed to wild type H. pylori (Figure 3.2a; third and 
fourth panels). Induction of the genes by 6hrs suggests that these innate genes are early 
response genes and it is likely that shared signal transduction events are involved in the
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(a) (b)
Control
hBD2
hBD3
COX-2
GAPDH
Figure 3.2 Time course of induction of host defence genes by (a) Helicobacter pylori
I
and (b) IL-ip. Confluent AGS cells were infected with (a) wild type H. pylori strain 
26695 ( lx l0 8cfu/ml) or (b) IL-1(3. Gene expression was compared to levels in control 
untreated cells for each gene of interest. Results shown are representative data from three 
experiments.
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hBD3■
IL-8
S3B3 GAPDH
Figure 3.3: Innate immune expression with different clinical H. pylori strains.
AGS cells were infected with several H. pylori strains ( lx l0 8cfu/ml). Results were obtained 
by RT-PCR analyses. Lane A shows control unstimulated cells, Lanes B and C correspond 
to cells treated with H. pylori strains J 150 and J99 respectively.
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regulation of their gene expression. To further the above findings the study was expanded 
beyond the more virulent cytotoxic strains (60190, 84-183, 26695) and investigated the 
host innate immune response to less virulent strains. J150 (cagPAI-ve, s2/m2) and J99 
(cagPAI+ve, sl/m2 VacA) strains were utilised. hBD2 expression was more modest when 
cells were infected with less virulent strains compared to cytotoxic strains (Figure 3.1; 
Lanes D and E compared to Figure 3.3 Lanes B and C), and in particular the cagPAI-ve 
strain J150 exhibited minimal hBD2 and IL-8 expression when compared to cagPAI+ve 
strains (Lane B). There was no significant difference noted in the expression of hBD3 gene 
expression in response to ozgPAI-ve strains compared to cagPAI+ve H. pylori strains 
(Figure 3.3; Lanes B and C, third panel).
3.2 Role of bacterial virulence determinants in mediating differential p-defensin 
expression (RT-PCR)
In order to explore potential bacterial factors involved in the modulation of P-defensin 
regulation, studies utilising isogenic mutants (derived from H. pylori 60190) were conducted. 
The isogenic mutants lacking the bacterial effector protein, CagA-ve and disruption of the 
type IV secretion apparatus, cagE-ve, from parent wild type strains were employed in 
preliminary experiments to determine differential expression of innate immune genes. 
Additionally a strain lacking the vacuolating toxin (vacA-ve) and one lacking the entire 
pathogenicity island (Tx30a) was included. Bacterial-AGS co-culture studies were performed 
and data for p-defensin expression obtained 8h post-infection by RT-PCR are shown in 
Figure 3.4. Although previous studies have suggested a CagPAI requirement for IL-8 
production (Crabtree et al., 1999, Fischer et al., 2001, Munzenmaier et al., 1997, Naumann, 
2000, Selbach et al., 2002, Viala et al., 2004), this is the first time isogenic mutants have 
been employed to investigate potential differential hBD expression.
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Figure 3.4: Modulation of human p-defensin expression during H. pylori infection.
AGS cells were co-infected with wild type H. pylori strains (60190 and 84-183), isogenic 
(vacA, cagA, and eagE) mutants of strain 60190,) and a strain lacking the cagPAl (Tx30a) 
(MOI=100). hBD2 (a) and hBD3 (b) gene expression 8h post-infection was determined and 
normalised to GAPDH. Increases in mRNA levels are expressed as n-fold induction 
compared to uninfected control cells. Data shown is mean (± SEM; * p< 0.05) induction of 
three independent experiments.
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Infection in the presence of cytotoxic strains 84-183 and 60190 caused a significant (p 
<0.05) increase in hBD2 gene expression, as described earlier. Both the cagA and vacA 
mutant strains were able to induce hBD2 gene expression to a similar extent as the wild 
type parent strains (Figure 3.4a). In contrast, no significant increase in hBD2 gene 
expression over control was observed during infection with either the 60190 eagE mutant 
or strain Tx30a, suggesting that the type IV secretion system plays a critical role in hBD2 
gene expression.
For hBD3, an approximate 2.5- to 3-fold increase (p <0.05) in mRNA expression was noted 
during infections in the presence of the wild type strains verifying our previous results. As 
observed for hBD2 gene expression (Figure 3.4a), the absence of the CagA and VacA 
virulence factors did not affect the degree of hBD3 mRNA induction (Figure 3.4b), 
suggesting these two bacterial proteins do not play a significant role in H. /Ty/on'-mediated p- 
defensin gene expression.
A role for an intact CargPAI in mediating IL-8 gene expression was confirmed, and 
comparably to hBD2 and -3, there did not seem to be a role for the bacterial CagA in the 
regulation of IL-8 mRNA expression (Figure 3.5). Interestingly, both IL-18 and COX-2 gene 
expression was found to be less dependent on the presence of the CargPAI in this series of 
experiments (Figure 3.5), indicating that these innate immune genes are regulated by 
CflrgPAI-independent mechanisms.
3.3 Role of bacterial virulence determinants in mediating differential p-defensin 
expression (Transfection analyses)
(a) Optimisation studies with IL-8, NF-kB promoters in HEK 293 cells
To confirm and verify the findings from the RT-PCR analyses, transfection experiments 
with innate defence promoter constructs were conducted. Preliminary studies optimising
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Figure 3.5: Expression of innate immune genes by H. pylori isogenic mutants. AGS
cells were infected with several Isogenic H. pylori mutants ( lx l0 8cfu/ml). RNA from 
infected gastric epithelial cells was amplified by RT-PCR. Lane A shows control 
unstimulated cells, Lane B represent cells stimulated with wild type strain 84183. Lane C 
and D correspond to cells treated with cagA negative and eagE negative isogenic mutants 
from parent strain 84183, respectively. A panel of innate immune genes was studied and 
experiments were carried out three times, a representative result is shown. Lane E was 
included for a positive control with IL-lp stimulated AGS cells.
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experimental conditions were conducted utilising NF-kB and IL-8 promoter constructs in 
HEK 293 cells. These cells were chosen prior to investigating AGS cells as HEK 293 cells 
are known to exhibit high transfection ability. Various parameters (e.g. amount of DNA 
transfected, time of reaction etc) were optimised and a representative experiment is shown 
in Figure 3.6. HEK 293 cells transfected with either IL-8 or NF-kB promoters were 
stimulated with IL-1 p or wild type H. pylori and luciferase activities measured. Significant 
induction (5-18 fold) of both IL-8 and NF-kB expression in the presence of infection with 
H. pylori was observed (Figure 3.6), however, the level of induction was less dramatic, 
only 2-fold induction when IL-1 p was used to stimulate cells. A consistent increase in the 
level of promoter luciferase activity was noted for IL-8 compared to NF-kB, which may be 
accounted for by the various transcription factor binding sites in addition to NF-kB 
regulating IL-8 promoter activity.
(b) Studies with hBD2 and -3 in AGS cells
The full length (2kB) hBD2 promoter was constructed in our laboratory (Mr Shao Wang, 
London, UK; personal communication) and the hBD3 promoter was a kind gift from Ole 
Sorensen (Lund University, Sweden), therefore it was pertinent to firstly ascertain the 
functional (i.e., inducible promoter activity) of the two reagents. Transfections were 
conducted as before in HEK 293 cells using 60ng hBD2 promoter plasmid per well. Each 
experimental condition was carried out in triplicate. hBD2 luciferase promoter construct 
exhibited significant increased activity upon both bacterial and cytokine stimulation (Figure 
3.7). An approximate 5 fold induction was observed. As the optimal conditions of 
transfection for hBD2 promoter had not been established, studies using another transfection 
method were carried out by the use of peptide-mediated transfection as an alternative to 
Fugene transfection reagent (data not shown).
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Figure 3.6 H. pylori is a potent inducer of IL-8 and NF-kB. HEK 293 cells were 
transiently co-transfected with pRL-TK-luciferase and pGL3-control vector and either NF- 
kB or IL-8 promoter luciferase reporter plasmids (total 230ng DNA) and incubated for 24h. 
IL-lp (20ng/ml) or H. pylori (strain 60190 lx l08cfu/ml) were added for 16h before cells 
were harvested in passive lysis buffer. Promoter luciferase activities were analysed by 
luciferase reporter assay system and normalised using pRL-TK-luciferase activity {Renilla 
luciferase activity) in each sample. Data represent the mean (fold induction from 
unstimulated controls) of three independent experiments ± S.D. of triplicates.
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Figure 3.7 H. pylori induces hBD2 promoter activity in HEK 293 cells. HEK 293 cells 
were transiently co-transfected with pRL-TK-luciferase and pGL3-control vector and 
hBD2- luciferase reporter gene vector using Fugene transfection reagent. After 24h 
incubation, cells were stimulated with H. pylori (strain 60190 lx l08cfu/ml) for 16h. Cells 
were harvested in passive lysis buffer and luciferase activity was measured as described 
above. Data represent the mean (fold induction from unstimulated controls) ± S.D. of 
triplicates.
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Once hBD2 transfection conditions were established in HEK 293 cells, subsequent 
experiments were performed in AGS cells. Cells were co-transfected with innate immune 
promoter luciferase constructs (hBD2, hBD3 or IL-8), Renilla luciferase and pGL3-control 
(pcDNA 3.1) vector 24h prior to stimulation with IL-1 P or wild type H. pylori for 8h 
(Figure 3.8). Promoter activities were analysed by luciferase reporter assay and fold 
increase in activity was compared to that of uninfected control cells. Importantly, in spite of 
lower transfection efficiency, AGS cells had a similar fold induction of promoter luciferase 
relative to Renilla luciferase activity to that seen in HEK 293 cells. IL-ip induced a 4 fold 
increase in hBD2 and IL-8 promoter activities (Figure 3.8) and a 2.5-3.5 fold induction was 
observed for H  /?y/or/-mediated promoter activities for hBD2, hBD3 and IL-8 (Figure 3.8). 
The induction observed in promoter luciferase activity for IL-8, hBD2 and -3 matched 
results from the RT-PCR studies as IL-ip potently induced IL-8 and hBD2 expression 
whereas H. /^/orz-mediated expression was highest for hBD3.
Once the increase of p-defensin promoter activities by cytotoxic H. pylori was established, 
the role of bacterial virulence factors in promoter activation was investigated. The results of 
representative transfection experiments are shown in Figure 3.9. A significant (p <0.02) 
increase in hBD2 promoter activity was observed during infection with H. pylori strains 
60190 and 84-183. Infections in the presence of isogenic cagA and vacA mutant strains 
confirmed that these bacterial effectors play a minimal role in modulating epithelial innate 
immune responses, whereas the eagE mutant and strain Tx30a failed to elicit an hBD2 
response (Figure 3.9a). Analysis of hBD3 promoter activity in response to a range of 
bacterial strains revealed a significant increase (p <0.05) in the presence of H. pylori strains 
60190 and 84-183 and the isogenic vacA and cagA mutant strains (Figure 3.9b). 
Interestingly, a modest increase in hBD3 promoter activity over control was observed for
eagE mutant and strain Tx30a; however this increase did not reach statistical significance.
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Figure 3.8 Innate immune promoter activities in AGS gastric epithelial cells.
AGS cells were transiently co-transfected with luciferase reporter gene plasmids (IL-8, 
hBD2 and hBD3), pRL-TK-luciferase and pGL3-control vector using Fugene transfection 
reagent. Cells were either infected with H. pylori (strain 60190 lx l0 8cfu/ml) or stimulated 
with IL-ip (20ng/ml) for 16h after 24h. Cells were harvested in passive lysis buffer and 
luciferase activity was assayed. Data represent the mean fold induction from unstimulated 
controls ± S.D. of triplicates.
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Figure 3.9: hBD2 and hBD3 promoter activity in response to infection.
AGS cells were transiently transfected with (a) hBD2 or (b) hBD3 promoter-luciferase 
constructs. Cells were exposed to wild type and isogenic mutant H. pylori strains for 8h. 
Data are expressed as n-fold increase in luciferase activity when compared to uninfected, 
control cells. Error bars indicate SEM of values representative of two to three experiments 
conducted in triplicates.
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These findings suggest a minimal role for CagA and VacA as observed for the hBD2 
promoter. Further, the increase in hBD3 promoter activity in the absence of a type IV 
secretion system (CagE, Tx30a) implicates the involvement o f signalling events distinct 
from those involved in hBD2 gene regulation.
In order to identify specific elements responsible for the hBD2 promoter induction 
observed during H. pylori infection, a truncated construct containing the following binding 
sites (Lu et al., 2004) was made available for this study (H. Kai, Kumamoto University, 
Japan).
ETS NFkB HFkB NFIM
Experiments were undertaken as before where transient transfection allowed for the 
introduction of the constructs into AGS cells. Cells were then exposed to two wild type 
strains (60190, 84-183), a CagPAI-ve strain (Tx30a) and IL-lp (Figure 3.10) for 8h before 
analysis of luciferase activities of the two constructs.
There was no significant difference observed between promoter activities regardless of the 
nature of the stimulation and the values were mirrored from approximately 3 fold induction 
with wild type to relatively no induction with Tx30a strain for both full length and 
truncated constructs (Figure 3.10). Since the truncated hBD2 (-247) promoter contains the 
main transcription factors involved in inflammatory responses including NF-kB, AP-1 and 
NF-IL6 (Lu et al., 2004) it may be argued that these elements are sufficient for full 
activation of hBD2 promoter activity. However, since the contribution of any other factors 
present in the full length construct during H. pylori infection is not known, the full length 
promoter was utilised in subsequent experiments.
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Figure 3.10 Full length and truncated (-247bp) hBD2 promoter constructs exhibit 
similar activity.
AGS cells were transiently transfected with full length (2kb) or truncated (247bp) 
promoter-luciferase constructs prior to exposure to wild type strains, Tx30a strain, or IL-1 (3 
for 8h.,No significant difference in activity was observed between the full length or 
truncated hBD2-luciferase promoter constructs. Data are expressed as n-fold increase in 
luciferase activity when compared to uninfected, control cells and error bars indicate SEM 
of values.
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In conclusion, induction of hBD2 and hBD3 expression by wild type H  pylori strains both 
by mRNA and promoter analyses was found. Interestingly, a minimal role for the bacterial 
factors CagA and VacA in eliciting host innate epethial immune response was observed. 
We confirmed CagPAI-dependent IL-8 expression and furthermore revealed COX-2 and 
IL-18 seem to be regulated by CogPAI-independent mechanisms as mRNA levels remained 
unchanged during infection with an array of isogenic mutants.
Transient transfections utilising two separate cell-lines confirmed bacterial-mediated (3- 
defensin induction as observed in earlier RT-PCR experiments. Both techniques suggested 
a critical role for the CagPAI in hBD2 but not hBD3 gene regulation.
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CHAPTER 4 
Role of H. /^ /0 /7-mediated NF-kB 
Activation in p-defensin Gene Regulation
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4.0 Background
(a) Signalling pathways leading to NF-kB activation
Our understanding of host innate immune responses to infectious agents has leaped
manifold in recent years. Research in the last decade has identified a series of pattem-
recognition receptors (PRRs) that are intimately involved in recognising invariant
structures or pathogen-associated molecular patterns (PAMPs) on micro-organisms (Akira
and Takeda, 2004, Akira, 2006, Franchi et al., 2006). The best characterised pattern
recognition receptors include the Toll-like receptors (TLRs), a family comprising
evolutionarily conserved, transmembrane proteins that recognise microbial components
such as LPS, flagellin and peptidoglycan and have the ability to transduce signals leading
to production of cytokines, chemokines and antimicrobial peptides (Biragyn et al., 2002,
Hertz et al., 2003, Ozato et al., 2002, Wang et al., 2003b, Laube et al., 2006, Pasare and
Medzhitov, 2005). The extracellular domains of TLRs comprise leucine rich repeat (LRR)
motifs and the cytoplasmic signalling domain shares significant homology with interleukin-
1 receptor (IL- 1R) sequence, the homologous region is known as Toll/IL-IR (TIR) domain
(Bowie and O'Neill, 2000). Initial interaction of ligand or PAMP and its specific PRR leads
to (homo/hetero) dimerisation of TLRs, followed by recruitment of adaptor proteins {via
TIR-TIR domain interactions). Adapter proteins include myeloid differentiation factor 88
(MyD88), TIR-associated protein (TIRAP)/MyD88-adaptor-like (MAL), TIR-domain-
containing adaptor protein inducing IFN-(3 (TRIF) or TRIF-related adaptor molecule
(TRAM) (Akira et al., 2006, Takeda and Akira, 2005). These adaptor molecules in turn
may recruit IL-lR-associated kinases (IRAKs) and associate with tumour necrosis factor
(TNF) receptor (TNFR)-associated factor (TRAF) 2, 3 or 6. Activation of several upstream
kinases including I kB  kinase (IKK), TANK-binding kinase (TBK)l and TGF|3-activated
kinase (TAK)l culminates in phosphorylation of inhibitory IkB proteins. This event leads
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to dissociation of these inhibitory proteins from the NF-kB complex, freeing the latter to 
translocate to the nucleus to function as a “transcription factor” (Ghosh and Karin, 2002, 
Karin, 2004).
(b) H. pylori-mediated NF-kB activation
It is well established that adherence of H. pylori to gastric epithelial cells activates multiple 
signal transduction events, leading to IL-8 gene transcription. Previous studies have shown 
that activation of transcription factor NF-kB plays a critical role in the regulation of host 
epithelial innate immune responses (Keates et al., 1997, Sharma et al., 1995, Glocker et al., 
1998, Munzenmaier et al., 1997). Current understanding of H. pylori-medmtQd TLR 
signalling events in activated epithelial and/or monocytic cells is outlined in Figure 4.1.
The main TLR implicated in recognition of LPS of Gram-negative bacteria is TLR4. TLR 4 
mRNA has been detected in human gastric epithelial cell-lines (Backhed et al., 2003, Su et 
al., 2003), however, the biological relevance of TLR4 receptor on human gastric cells 
remains unclear as cells are generally unresponsive to H. pylori LPS (Backhed et al., 
2003). Also, addition of a neutralising antibody to TLR4 does not block bacterial-mediated 
IL-8 production (Su et al., 2003). The known low biological activity of H. pylori LPS 
(Moran et al., 2005), combined with variation in expression of signalling components of 
the TLR4 pathway leaves the data at present inconclusive (Smith, Jr. et al., 2003, Su et al., 
2003). In contrast to human studies, guinea pig gastric cells, do respond to H. pylori LPS, 
suggesting species variation (Kawahara et al., 2001). Interestingly, unlike epithelial cells, 
effect of H. pylori LPS in NF-kB activation in human monoctyic cells is more convincing 
(Bhattacharyya et al., 2002).
TLR2 plays an important role in the detection of several bacterial signature motifs
including lipoteichoic acid (LTA), lipoproteins and peptidoglycan (PGN) (Akira et al.,
2006) with TLR5 responsible for the recognition of flagellin (Hayashi et al., 2001). The
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exact contribution of epithelial TLR2 and TLR5 in H. pylori detection remains ambiguous 
as human embryonic kidney (HEK) 293 cells show bacterial-mediated IL-8 expression in 
the absence o f TLR2 (Backhed et al., 2003, Schmausser et al., 2004). Also H. pylori 
flagellin elicits minimal IL-8 activation despite expression of functional TLR5 in adult 
gastric epithelium (Gewirtz et al., 2004). A recent investigation detailing H. pylori and 
Campylobacter je juni flagellin suggest specific mutations in the flagellin molecule has 
obliterated TLR5 detection, whilst compensatory changes have allowed preservation of 
flagellar motility (Andersen-Nissen et al., 2005).
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Figure 4.1 Model of H. pylori cagPAI-dependent and -independent activation of host 
epithelial innate immune responses (adapted from Lee and Josenhans, 2005). 
Downstream signalling blockage by A46 and A52 viral proteins is indicated (Bowie et 
al, 2000).
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This clearly provides an immune evasion mechanism for the bacteria without 
compromising motility, a process essential for successful colonisation and pathogenesis.
A second family of PRRs, cytoplasmic nucleotide-binding oligomerisation domain (NOD) 
proteins, have also been implicated in epithelial host innate immune responses to infection. 
NODI (encoded by the caspase-recruitment domain 4 gene, CARD4) and NOD2 (encoded 
by CARD15) recognise peptidoglycan (PGN), a component of bacterial cell walls and like 
the TLRs, rely on recognition of pathogens by a leucine rich repeat (LRR) domain (Inohara 
and Nunez, 2003, Inohara et al., 2005, Franchi et al., 2006). Specifically, NOD1/G4&D4 
distinguishes its ligand, y-D-glutamyl-meso-diaminopimelic acid (iE-DAP) and 
NOD2/G4i?D/5 senses muramyl dipeptide (MDP) (Chamaillard et al., 2003, Girardin et 
al., 2003). Since both Gram-negative and Gram-positive bacteria contain MDP, NOD2 is a 
more global bacterial sensor compared to NODI (Strober et al., 2006).
Elegant studies by Viala and colleagues suggest a major role for gastric epithelial NODI in 
detection of H. pylori (Viala et al., 2004). Bacterial sensing was found to be dependent 
upon the presence of an intact cagPAI; thus implicating the type IV secretion system as a 
conduit for the intracellular delivery of bacterial iE-DAP (Viala et al., 2004). NOD1- 
dependent activation of known downstream signalling pathways is also depicted in Figure 
4.1. Viala and colleagues also provided evidence for a role for NODI in vivo, as NOD1- 
deficient mice were found to be more susceptible to infection by cagPAI positive strains 
than wild type mice.
(c) H. pylori-mediated p-defensin expression
The role of hBDs in H. pylori infection both in vitro and in vivo has been recently evaluated
(Bajaj-Elliott et al., 2002, George et al., 2003, Hamanaka et al., 2001, Lee and Josenhans,
2005, O'Neil et al., 2000, Wada et al., 2001). Although, hBDl expression is constitutive, it
can be further modulated in vitro and in vivo in response to H. pylori (Bajaj-Elliott et al.,
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2002). In contrast, hBD2 expression is induced by H. pylori infection (Bajaj-Elliott et al., 
2002, O ’Neil et al., 2001). Furthermore hBD2 induction in MKN45 gastric cells was found 
to be up-regulated via participation of the CagPAI in a NF-kB-dependent manner (Wada et 
al., 1999, Wada et al., 2001). hBD2 regulation has been studied in detail revealing four NF- 
kB binding sites involved in its transcriptional regulation. Several studies suggest that the 
proximal NF-kB binding site is critical for hBD2 gene expression in intestinal and gastric 
epithelia (Figure 4.2; Ogushi et al., 2004, Tsutsumi-Ishii and Nagaoka, 2003, Vora et al., 
2004, Wada et al., 2001, Wehkamp et al., 2004).
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Figure 4.2 NF-kB and AP-1 contribute to hBD2 transcriptional regulation.
Previous work has also shown that although H. pylori can activate p65-p65, p50-p50 and 
p65-p50 homo- and hetero-dimer formation, it is the p65-p65 homodimer that binds to 
hBD2 promoter region (Wada et al., 2001). Although a role for NF-kB in bacterial 
mediated hBD2 expression is established, upstream signalling events leading to NF-kB 
activation and hBD2 induction during H. pylori infection have not been studied.
Further, to date, no studies have investigated the regulation of hBD3 expression during H. 
pylori infection. Up-regulation of hBD3 gene expression by wild type bacteria found in 
chapter three has now been reported (George et al., 2003).
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4.1 A major role for IkBck but not IkB0 in H. /?y for/-mediated NF-kB activation
Phosphorylation and subsequent degradation of IkB proteins is a well-established upstream
event prior to NF-kB nuclear translocation. Although several studies have previously
shown IkBcx degradation in response to H. pylori, confirmation of this event was sought in
this co-culture system, mainly to validate the infective nature of the wild-type bacterial
strains being utilised in this thesis. Secondly, degradation of IicBa would be indicative of
integrity of NF-kB associated pathways in AGS cells- the choice of gastric cell-line
employed. Detectable levels of IkBci were present in control unstimulated AGS cells
(Figure 4.3-4.5). Exposure to two cytotoxic wild type H. pylori (60190 and 84-183) strains
resulted in rapid (15-30min) IkB cx degradation with protein levels returning to that of
control by 60min (Figure 4.3). These findings are comparable to those of Nozawa et al,
2002, where H. pylori strain 43504 was investigated. Although several studies have shown
H. pylori-mediated NF-kB activation (Bhattacharyya et al., 2002, Glocker et al., 1998,
Keates et al., 1997, Nozawa et al., 2002, Wada et al., 2001), this study is the first detailing
kinetics of IkBo, degradation. Stimulation of AGS cells by IL-1 p (positive control) also led
to degradation o f IkBcx, interestingly, the kinetics o f IkBcx degradation by IL-ip paralleled
those observed in H. pylori treated cells (Figure 4.3 compared with Figure 4.4).
Most studies to date have concentrated on the role of IicBa in H. pylori-mediated NF-kB
activation, however, in cells nearly half of NF-kB resides complexed to another major
inhibitory protein isoform, IkBP (Whiteside et al., 1997). The potential role of IkBP in H.
pylori-mediated NF-kB activation was assessed. For this purpose, IkBP expression during
infection was followed. Level of IkBP in unstimulated, control AGS cells was found to be
much lower than that observed for IkBci (Figure 4.3 versus Figure 4.5). No IkBP
degradation was observed either during cytokine or bacterial stimulation, this effect was
followed up to 4h post-activation (Figure 4.5). Interestingly, instead of degradation increase
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Figure 4.3 Rapid degradation of inhibitory protein IkBo in H. pylori infection.
AGS cell monolayers were infected with live wild type cytotoxic strains (a) 60190 and (b) 
84183 (1x10s cfu/ml). Time course o f NF-kB activation was evaluated by subjecting cell 
lysates to SDS-PAGE and Western Blotting. Equal protein loading was confirmed by 
reprobing the blot with a P-actin antibody. Experiments were conducted three times and a 
chosen representative blot is shown.
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Figure 4.4 IL-lp induces the degradation of IkBcx.
AGS cells were co-cultured with IL-lp (20ng/ml) for the indicated time course. Cell lysates 
were subjected to SDS-PAGE, Western Blotting and activation o f N F - k B  was followed by 
degradation of IkBcx. Equal protein loading was confirmed by reprobing the blot with a p - 
actin antibody. Experiments were conducted three times and a chosen representative blot is 
shown.
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Figure 4.5 Inhibitory protein, IkBP is not degraded during H. pylori infection. Cell
lysates from (a) H. pylori (60190; lx l0 8 cfu/ml) infected AGS cells were subjected to SDS- 
PAGE and Western Blotting. No obvious degradation of IkBP was observed up to 4h post­
infection or (b) IL -lp (20ng/ml) stimulation. Experiments were conducted three times and a 
chosen representative blot is shown.
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in the amount of IkBP at 60-90min with IL-lp, and 3-4h post-bacterial infection was 
observed.
4.2 P65 phosphorylation is not involved in H. py/ori-mediated NF-kB activation
Once NF-kB is released from the constraints of its inhibitory proteins, further modification 
of p65 subunit may occur via phosphorylation and acetylation (Bird et al., 1997). Protein 
post-translational modifications are a general mechanism employed to regulate protein 
function. To date, no studies have reported epithelial p65 phosphorylation status during H. 
pylori infection. In the present study, p65 phosphorylation status was investigated in our 
established in vitro model system. A modest increase in the levels of phosphorylated p65 2- 
3h post infection when compared to unstimulated control AGS cells was observed (Figure 
4.6a). P65 phosphorylation was followed for up to 3h and no longer as a second wave of 
NF-kB activation is known to occur at later time-points (Papaccio et a l , 2005).
Interestingly, in contrast to bacterial stimulation IL-lp caused a rapid and potent transient 
increase in phosphorylated p65 which was noted as early as 30min (Figure 4.6b). Maximal 
levels were attained at 60min after stimulation. These experiments suggest differential 
regulation of NF-kB activation in response to cytokine and bacterial stimuli.
4.3 NF-kB is involved in the regulation of hBD2 and IL-8 but not hBD3 gene expression
To evaluate any potential contribution of NF-kB in IL-8 and (3-defensin gene regulation,
infections in the presence of MG 132, a specific proteasome inhibitor were conducted. AGS
cells pre-treated with MG 132 were exposed to H. pylori for 8h and samples analysed by
RT-PCR and promoter luciferase activity. There was a striking inhibition of hBD2 and IL-8
expression in the presence of MG 132 compared to cells infected with bacteria alone (Figure
4.7a), this is likely to be related to the inhibitors ability to prevent proteasomal degradation
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Figure 4.6 Evaluation of p65 phosphorylation during H. pylori-mediated NF-kB
n
activation. Infection with (a) H. pylori (strain HP 60190, 1x10 cfu/ml) or stimulation with
(b) IL-lp (20ng/ml) was carried out for up to 3h. Whole cell lysates were subjected to 
Western Blotting for phospho-specific p65. A non-phospho p65 antibody was used to 
demonstrate equal levels of p65 protein. Experiments were conducted at least three times 
and a chosen representative blot is shown.
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of IkB proteins. A dramatically significant reduction in hBD2 (>80% inhibition) promoter 
activity (p<0.05; Figure 4.7b) and more than 60% inhibition for IL-8 was also observed. In 
contrast to its effect on hBD2 promoter function, MG 132 had no significant effect on hBD3 
activity (Figure 4.7b). This confirms previous work highlighting a critical role of NF-kB in 
mediating hBD2 expression (Wada et al., 2001, Wehkamp et al., 2004) the present study, 
however, is the first defining a minimal role for NF-kB in hBD3 gene regulation.
4.4 H. pylori induces epithelial IL-8 and p-defensins by IL-lp- and TLR- independent 
mechanisms
Studies investigating innate defence in skin suggest that direct microbial stimuli results in a
modest induction in hBD2 expression; this increase however, is dramatically enhanced in
the presence of other innate immune cells and their secretory products (Liu et al., 2003,
Sorensen et al., 2005). For example, it has been shown that LPS-stimulated macrophages
secrete IL-lp which further enhances hBD2 induction in a paracrine fashion (Liu et al.,
2003). To elucidate if H. j5y/on'-mediated NF-kB activation and subsequent hBD2 gene
expression was a result of direct microbial assault or an indirect, autocrine effect of IL-ip
release during infection, several approaches were followed. Firstly, any potential induction
of IL-ip mRNA in our co-culture experiments was investigated, no expression of IL-lp
during the 24h period of infection was observed (data not shown). Secondly, the effect of
exogenous IL-1 receptor antagonist (IL-1RA) was evaluated by conducting cytokine and
bacterial stimulation of AGS cells in the presence and absence of IL-1RA (Figure 4.8). In
the presence of IL-lp or H. pylori an increase in hBD2 was noted compared to unstimulated
control cells, with greater induction of hBD2 in response to IL-ip (Figure 4.8; lane B).
Inclusion of IL-1RA caused a dramatic inhibition of hBD2 gene expression in IL-ip-
stimulated cells (Figure 4.8; lane B compared to lane C), whereas H. /?y/on-mediated hBD2
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H. pylori 
infected
+ MG132
hBD2
GAPDH
■  H. pylori 
□  H. pylori +MG132
IL-8 hBD2 hBD3
Figure 4.7 A potential role of NF-kB activation in H. pylori-mediated IL-8 and hBD2 
but not hBD3 gene regulation.
(a) Cells were pre-treated with 25pM MG 132, a specific proteasome inhibitor, prior to 
exposure to wild type H. pylori strain 60190 for 8h and RT-PCR analyses were conducted. 
A representative o f three independent experiments is shown, (b) Transient transfection 
experiments were undertaken introducing promoter-luciferase constructs into AGS cells 
24h prior to inhibitor pre-treatment and infection with H. pylori. Significant (* p<0.05) 
reduction of IL-8 and hBD2 promoter activities was observed. Experiments were conducted 
in triplicate and repeated three times.
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Figure 4.8: H. /?j/6>/7-mediated innate immune gene expression is independent of 
IL-ip.
AGS cells were stimulated with IL -ip (20 ng/ml) or H. pylori (1x10s cfu/ml) for 8h both in 
the presence or absence of IL-1RA (200 ng/ml). Innate immune gene expression was 
assessed by RT-PCR. A representative analysis of at least 3 independent experiments is 
shown.
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expression remained unchanged in the presence of the receptor antagonist (Figure 4.8; lane 
D compared to lane E). IL-ip caused a modest increase in hBD3 expression which was 
abolished by IL-1RA (lane B compared to lane C); in comparison, IL-1RA had no effect on 
H. pylori-mQdmted hBD3 expression (Figure 4.8; Lane D compared to Lane E). IL-8 
expression was also explored and we found that in the presence of IL-1RA, H. pylori- 
mediated IL-8 expression was unaffected (lane D compared to lane E). Taken together, this 
data suggests IL-8 and hBD2 induction during H. pylori infection is independent of 
autocrine IL-ip production.
Finally, to identify if IL-1 p and/or TLR-signalling components are involved in H. pylori- 
mediated NF-kB activation and hBD2 expression, two well characterised Vaccinia virus 
encoding proteins, A46R and A52R, which antagonise components of IL-ip and TLR 
signalling pathways were employed (see Figure 4.1; Bowie, et al., 2000). A52R has no 
apparent homology to host proteins whereas A46R contains a TIR domain, thus distantly 
related to its mammalian IL-1R/TLR family (Bowie et al., 2000). Dr Andrew Bowie and 
colleagues have conducted extensive studies detailing mechanism(s) of viral immune 
evasion and have revealed that A46R and A52R block ILlR/TLR-mediated NF-kB 
activation. Specifically, A52R disrupts host signalling by associating with TRAF6 and 
IRAK2 and A46R targets TIR-domain containing adaptor molecules such as MyD88 and 
MAL (Figure 4.1; Harte et al., 2003, Stack et al., 2005). Either way both viral proteins 
prevent downstream signalling and NF-kB activation. Plasmids encoding A46R and A52R 
were co-transfected with IL-8 and hBD2 promoter-constructs prior to stimulation with H. 
pylori or IL-1 P (Figure 4.9). If there was paracrine IL-lp secretion or the TLRs were 
involved in the induction of hBD2, one would expect the antagonists to prevent up- 
regulation of hBD2 gene expression. A significant reduction of IL-8-luciferase activity in 
the presence of A46R and A52R was observed (p<0.05) in IL-ip-stimulated cells but there
□  IL-8 +A46R
IL-13  H p 6 0 1 9 0
(b)
□  hBD2 +A46R
IL-13  Hp 6 0 1 9 0
Figure 4.9 H. pylori- mediated innate immune gene expression is independent of IL-lp 
or TLR- signaling pathways.
AGS cells were transiently transfected with A46R and A52R plasmids along with (a) IL-8 
or (b) hBD2 promoter construct for 24h prior to bacterial or cytokine stimulation. Values 
are expressed as mean ±SEM from a representative of three experiments conducted in 
triplicates. Inhibition of IL-1 p stimulation in the presence of both A46R and A52R was 
statistically significant * p < 0.05.
was no significant effect on H. pylori-mediated IL-8 promoter function (Figure 4.9a). 
Similarly, the presence of A46R and A52R showed no effect on H. pylori-induced hBD2 
regulation but a remarkable reduction (<60% and 70% inhibition respectively) on IL-1 P 
mediated hBD2 expression was observed (Figure 4.9b). Collectively, these observations 
indicate a direct bacterial-mediated effect on IL-8 and hBD2 gene expression which is TLR- 
independent. Further, no secondary autocrine role for IL-lp on epithelial innate response 
was found, however, this data does not rule out paracrine effects of IL-lp on hBD2 
expression in vivo.
4.S NODI: a critical player in hBD2 but not hBD3 gene regulation
As this study suggested hBD3 gene expression to be NF-kB independent (Figure 4.7), any 
potential role of NODI in regulation of hBD3 expression was not investigated. As 
experiments (Figure 4.9) described above suggested a minimal role for TLRs in P-defensin 
gene regulation, it was hypothesised that bacterial recognition by NODI may play a role in 
H. py/on'-mediated N F-kB activation and hBD2 gene expression. For this purpose, firstly, 
NODI gene expression was verified in AGS cells. NODI mRNA was found to be 
constitutively expressed in control uninfected cells and expression remained throughout the 
infection period, in the presence of all three wild type cytotoxic strains tested (60190, 
26695, 11637; Figure 4.10a). However, varying levels of NODI mRNA expression were 
noted for the different wild type strains; 60190, 26695 and 11637 (Figure 4.10a). Variation 
in NODI-expression during infection (compared to control) may represent inter- 
experimental variation and needs to be further verified by more quantitative techniques e.g. 
quantitative PCR and Western blotting. Importantly, infection in the presence of cagA, vacA 
and cagE isogenic mutants had minimal effect on NODI expression, suggesting these
virulence determinants do not modulate NODI expression as an immune evasion strategy.
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(a)
Con IL-ip 60190 26695 11637
NODI
GAPDH
(b)
Con IL-lp Hp CagA- CagE- VacA 
60190
NODI
GAPDH
Figure 4.10 NODI mRNA is expressed in AGS cells. Cells were either left unstimulated 
or exposed to three wild type cytotoxic strains of H. pylori (1x10s cfu/ml) for 8h prior to 
assessment by RT-PCR (a). NODI expression was detected in control and cells infected 
with isogenic mutants (b).
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N0D2 mRNA was not detected in control or infected AGS cells (data not shown). Next, 
experiments utilising a NODI siRNA encoding plasmid were conducted.
Introduction of double-stranded, small interfering RNA triggers specific degradation of 
targeted mRNA which is homologous to the introduced dsRNA, leading to effective gene 
silencing (Novina and Sharp, 2004). In the presence of NODI siRNA down-regulation of 
NODI in AGS cells was observed, which was verified both by the lack of gene (RT-PCR) 
and protein (Western blotting) expression (Figure 4.1 la and b). Cells were transfected with 
NODI or NOD2 (which was included as an internal negative control) siRNA plasmids prior 
to transfection of hBD2 or hBD3 promoter constructs. After further incubation, cells were 
exposed to appropriate stimuli. The presence of NODI or NOD2 siRNA in IL-lp stimulated 
cells caused a negligible reduction in hBD2 promoter activity (Figure 4.12), suggesting a 
minimal role for NODI in IL-lp mediated hBD2 expression. Since the IL-lp pathway has 
been well-characterised with the IL-1 receptor mediating downstream signalling events, 
lack of involvement of a microbial PRR such as NODI in IL-lp signalling was not 
unexpected. In contrast, hBD2 promoter activity was dramatically (p <0.05) reduced during 
H. pylori infection in the presence of NODI siRNA, thus highlighting a critical role for 
NODI in H. pylori-induced hBD2 gene expression. When similar experiments were 
conducted in the presence of the hBD3 promoter construct no effect of NODI or NOD2 
siRNA on IL-ip- or bacterial-mediated hBD3 expression was found (Figure 4.12b).
In addition, experiments were also executed utilising commercially available siRNA 
(Ambion Europe Ltd, Huntingdon, UK) targeting human NODI to complement results 
obtained in the presence of NODI siRNA plasmid (Figure 4.13). In the presence of NODI 
siRNA (referred to as ii in Figure 4.13), H. pylori-mediated hBD2 expression was 
significantly reduced (Figure 4.13), as observed with the siNODl-encoding plasmid (Figure 
4.12). No significant difference was detected in hBD3 promoter activity (Figure 4.13),
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(a)
Control NOD1 siRNA
NOD1
GAPDH
(b)
Control N0D1 siRNA
N0D1
p- actin
Figure 4.11 Small interfering NODI down-regulates NODI gene and protein 
expression. AGS cells were transfected with NODI siRNA encoding plasmid for 24h prior 
to evaluation o f (a) NODI mRNA and (b) protein.
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(a)
□  N O D 1 s iR N A
G9 N O D 2  SiR N A
H. p  6 0 1 9 0
h B D 3  a lo n e
□  N O D 1  siR N A
B  N O D 2  siR N A
Figure 4.12 NODI plays major role in hBD2 but not hBD3 expression.
AGS cells were transiently transfected with a plasmid encoding NODI or N0D2 siRNA 
24h prior to introduction of (3-defensin promoter constructs and 24h later, cells were 
stimulated with IL-1 (3 or H. pylori for 8h. Luciferase activities for (a) hBD2 and (b) hBD3 
were evaluated and error bars indicate SEM of values obtained from three independent 
experiments conducted in triplicates. Statistical significance was determined by t- test, * p 
<0.05.
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hBD2 hBD3
■  hBD alone 
□  NOD1 siRNA(ii)
Figure 4.13 Reduced hBD2 but not hBD3 gene expression in the presence of NODI 
siRNA.
AGS cells reverse transfected with siRNA for NODI (ii) 48h prior to the introduction of p- 
defensin promoter constructs and 24h later, cells were infected with H. pylori for 8h. 
Luciferase activities for hBD2 and hBD3 were evaluated and error bars indicate SEM of 
values obtained from three independent experiments conducted in triplicates. Statistical 
significance was determined by t- test, * p < 0.05.
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suggesting a major role for NODI in hBD2 but not hBD3 gene regulation. The present 
study is the first identifying NODI as a major signal transduction player involved in 
differential P-defensin gene expression.
4.6 NODI knock-out mice exhibited impaired murine p-defensin 4 expression during 
H. pylori infection
This series of experiments were performed by Professor G. Nunez and colleagues at the 
University of Michigan as part of a collaborative study. I am grateful to Professor Nunez 
for allowing me to include Figure 4.14 in this thesis.
In order to confirm a role for NODI in vivo, H. pylori infection in wild-type and NODI 
knock-out (KO) mice was investigated (experimental details in Boughan et al, 2006). 
Expression of murine P-defensin 4 (mBD4) a mouse orthologue of hBD2 was assessed 
(Schutte et al., 2002, Semple et al., 2005) from stomachs of infected mice. Seven days after 
infection, expression of mBD4 was clearly induced in the stomach of wild-type mice when 
compared to uninfected mice (Figure 4.14). In contrast, the expression of mBD4 was 
impaired in the stomach of NODI KO after H. pylori infection and values were comparable 
to uninfected mice. As a control, expression of mBD2 (another member of the p-defensin 
family) was also studied. Minimal mBD2 expression was noted in mouse stomach before 
and after H. pylori in wild-type and NODI KO mice when compared to ileal tissue 
(positive control), clearly indicating differential regulation of mBD2 and mBD4 in response 
to H. pylori infection (Figure 4.14). Interestingly, expression of macrophage inflammatory 
protein (MIP)-2, a functional analogue of the human interleukin 8, was more than twice as 
high in NODI KO mice than wild-type mice after exposure to H. pylori (Figure 4.14).
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Figure 4.14: Impaired murine p-defensin 4 (mBD4) expression in NODl-deficient 
mice after H. pylori infection.
Mice were inoculated intragastrically with H. pylori or PBS (uninfected) and sacrificed 7 
days post-infection. Results denote expression levels of indicated genes in the stomach 
tissue after normalisation to /?-actin as determined by quantitative Real-time PCR. 1 and 2 
represent experiment number; each derived from different mice and performed 
independently. Ileum denotes expression analysis in ileal tissue from a mouse.
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4.7 Conclusions
In the present study, a critical role for NODI in H. pylori-mediated NF-kB activation and 
hBD2 gene expression was established. In contrast, this pathway seems to play no 
significant role in hBD3 expression. This investigation is the first to highlight such 
potential differential regulation of hBD2 and hBD3 in any model of infection studied to 
date.
Although the transcription factor NF-kB has been implicated in both IL-lp and H. pylori- 
mediated hBD2 gene expression, very little is known about the regulation of hBD3 and this 
study is the first to investigate the regulatory mechanisms involved in hBD3 expression 
during an infection model. A minimal role for NF-kB in H. py/on'-mediated hBD3 
expression was found, which is not surprising in the context that no NF-kB binding sites 
have been identified in its promoter region (Wolk et al., 2004).
Since molecular interactions leading to NF-kB activation and identity of upstream
signalling events activated during H. pylori infection have remained unclear, the potential
role of these transduction events in bacterial-mediated innate defence was explored in the
present study. Firstly, time-dependent degradation of the inhibitory protein, IicBa, both
upon stimulation with IL-lp and wild type H. pylori was sought. While IicBa is the major
isoform of the inhibitory protein(s) studied by most researchers, NF-kB is known to be able
to bind and reside as a complex with other members of this family (Whiteside et al, 1997).
No role for IkBP protein in H. pylori infection was found. Western blotting is a semi-
quantitative technique and these observations require confirmation by other methods. This
series of experiments however, do suggest that H. pylori specifically activate NF-kB by
removal o f IicBa with IkBP/NF-kB complexes remaining sequestered in the cytoplasm and
playing a minimal role during infection. Unlike IidBa, IkBP does not possess a nuclear
export sequence (NES) and it has been proposed that this is required for newly synthesised
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IicBa to transport NF-kB back into the cytoplasm from the nucleus (Rodriguez et a\., 1999), 
so this may help explain the difference in degradation pattern observed between the two 
inhibitory proteins.
Also, evidence suggests stimulus-induced phosphorylation of NF-kB p65 subunit, can play 
a key role in transcriptional activation (Zhong, 2002); the contribution of this regulatory 
mechanism in H. pylori-mediated activation was explored. H. /ry/on-infected AGS cells did 
not induce the phosphorylation of p65 subunit, whereas IL-ip stimulated cells 
phosphorylated p65 rapidly. It is possible that experimental time frame limited detection of 
phosphorylated p65 in H. pylori infected cells as time course was conducted for 4h. This 
data highlights differential NF-kB activation in the presence of the two stimuli tested and 
provides one possible explanation as to the more potent induction of hBD2 expression in the 
presence of cytokine when compared to bacterial-mediated increase.
Establishing that p-defensin gene expression is directly mediated by bacterial cross-talk and 
not due to indirect cytokine effect was an important finding. Dramatic inhibition of hBD2, 
hBD3 and IL-8 expression was observed in IL-lp stimulated cells in the presence of its 
antagonist; however, IL-IRa had minimal effect on bacterial-mediated defensin expression. 
Also, minimal effect on IL-8 expression was noted in this study which reflects a previous 
study where the addition of an anti-ILlp antibody was unable to reduce H. py/on-mediated 
IL-8 levels (Nozawa et al., 2002). In spite of this, it is likely that IL-lp paracrine effects 
following release from inflammatory cells would be an additional stimulus to epithelial 
defence gene expression in vivo. A study investigating hBD2 expression in response to 
Escherichia coli LPS in the skin epidermis showed weak hBD2 expression, which was 
further amplified by the production of IL-1 p derived from monocytic cells which are 
present in the underlying tissue (Liu et al., 2003). The present study was confined to
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elucidating bacterial-epithelial cross-talk only and future studies should address the role 
and impact of other immune cells on bacterial-mediated defensin expression.
Studies performed in the presence of A46R and A52R showed marked inhibition of IL-1 p- 
induced hBD2 expression. However, the presence of A46R or A52R proteins had no effect 
on bacterial-mediated hBD2 expression. Taken together, these findings provide evidence to 
exclude both IL-ip and TLR signalling in mediating H. pylori-induced hBD2 expression.
A significant role for NODI in the detection of H. pylori by epithelial cells has been 
reported (Viala et al., 2004). Significant reduction of hBD2 but not hBD3 promoter activity 
in NODI siRNA transfected cells when exposed to H. pylori was observed, implicating 
NODI engagement in NF-kB mediated hBD2 expression. Furthermore, in vivo experiments 
investigating mBD4 (hBD2 orthologue) expression revealed that NODI KO mice exhibited 
impaired expression compared to wild type mice. The finding that MIP-2 was much higher 
in NODI KO mice than wild-type mice after exposure to H. pylori may be explained by 
increased H. pylori colonisation in the stomach of NODI KO mice and also highlights that 
unlike mBD4, MIP-2 gene expression is not exclusively dependent upon NOD activation 
(Viala et al., 2004).
A role for NOD2 in GI epithelial cross-talk with microbes is in its infancy. No expression 
of NOD2 in gastric AGS cells and no up-regulation was observed during infection. 
Interestingly, a very recent study has demonstrated that functional binding sites for NF-kB 
in the hBD2 promoter are required for NOD2-mediated induction of hBD2 through its 
ligand muramyl dipeptide (MDP) in primary keratinocytes (Voss et al, 2006). Together, 
these data suggest that NODI and NOD2 serve as intracellular pattern recognition 
receptors to enhance epithelial host defence by inducing the production of antimicrobial 
peptides such as hBD2 in response to infection.
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In conclusion, NODI engagement is a major pathway triggered in gastric epithelia upon H. 
pylori infection. NODI-driven NF-kB activation seems to regulate the expression of a 
subset of innate defence genes that include IL-8 and hBD2 but not hBD3.
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CHAPTER 5 
Role of H. /'/-mediated MAPK 
activation in p-defensin gene regulation
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5.0 Background
In addition to the ubiquitous NF-kB pathway, mitogen activated protein (MAP) kinase 
signal transduction pathways are also activated by stimuli that play a crucial role in 
regulation of immune-mediated inflammatory processes (Cuschieri and Maier, 2005, 
Hommes et al, 2003, Karin, 2004, Zhang and Dong, 2005). MAP kinases are 
serine/threonine kinases and comprise a three component, evolutionarily conserved, 
signalling cascade whereby a MAP 3-kinase phosphorylates a MAP 2-kinase, which in turn 
phosphorylates and activates a MAP kinase (Dong et al., 2002). The three main family 
members are extracellular signal-regulated protein kinases (ERK1/2) primarily activated by 
growth factors; c-jun amino terminal kinase (JNK) and p38 MAP kinase, which respond to 
the presence of growth factors but are preferentially activated to cellular stress and cytokine 
stimulation. For example, the most studied MAP 3-Kinase, Raf-1 activates MEK1/2 which 
in turn phosphorylates ERK1/2, however, investigations into the regulation of MAP 3- 
Kinases have proven to be very complex (Symons et al., 2006) as added cross-talk 
especially of upstream mediators means delineation of MAPK regulation in innate immune 
responses is likely to be equally complex.
The end result of MAPK signalling cascades is the activation of several transcription 
factors including activating transcription factor 2, ATF-2; Elk-1 and activating protein 1, 
AP-1. All three MAPK are known to activate the AP-1 family of transcription factors, 
which include the proto-oncogenes c-Jun, c-Fos and ATF-2 (Hommes et al., 2003). AP-1 
activates transcription of a number of target genes in growth-factor stimulated cells, and 
dysregulation of AP-1 has been implicated in abnormal cell growth leading to cancer 
(Meyer-ter-Vehn et al., 2000, Mitsuno et al., 2001).
Activation of transcription factor c-fos/c-jun (AP-1 complex) via the MAP kinase pathways
during H. pylori infection has been well studied (see Figure 5.1; Keates et al., 1999, Meyer-
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ter-Vehn et al., 2000, Mitsuno et al., 2001, Naumann et al., 1999, Naumann and Crabtree, 
2004, Torok et al., 2005).
MAP kinase 
cascades
MAPKKK
MAPKK
MAPK
Figure 5.1 H. pylori activates MAPK signal transduction cascades (taken from Meyer- 
ter-vehn et al, 2000).
Regulation of MAP Kinase-mediated p-defensin during gastrointestinal (GI) infection 
and inflammation
In addition to the three NF-kB bindings sites, there is one AP-1 binding site in the hBD2 
promoter (Figure 4.2) and mutation in this AP-1 site has diminished reporter activity in 
response to several PAMPs suggesting involvement of AP-1 in eliciting and regulating 
hBD2 expression (Ogushi et al., 2004, Vora et al., 2004, Wehkamp et al., 2004, Wehkamp 
et al., 2006).
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hBD3 and -4 are regulated by distinct NF-kB independent mechanism(s) and so far there 
are limited studies exploring these alternate pathways (Abiko et al., 2003, Buhimschi et al., 
2004, Fahlgren et al., 2004, Ganz, 2003, Harder et al., 2004, Niyonsaba et al., 2005, 
Sorensen et al., 2005, Varoga et al., 2005).
5.1 H. pylori activates MAP Kinase pathways in AGS epithelial cells
Prior to establishing a role for the MAPK in p-defensin gene regulation, it was pertinent to
confirm the activation of all three MAP kinase pathways in this co-culture system.
Confluent AGS monolayers were serum-starved overnight prior to infection with wild type
H. pylori strain 60190. For time-dependent studies, infected cell lysates were collected at
selective intervals and analysed for the activation of MAP Kinase pathways by Western
blotting (Figures 5.2-5.3). Phospho-specific antibodies for each of the MAP Kinase
(ERK1/2, JNK and p38) were used to detect activated protein levels during infection.
Detection of the corresponding inactive, non-phosphorylated form of each MAP kinase was
used as an internal control. H. pylori infection led to the activation of all three major MAP
Kinases (Figures 5.2 and 5.3). Co-infection of AGS cells by two different cytotoxic (60190,
84-183) strains led to rapid induction of the ERK pathway (Figure 5.2a and b). Two
immunoreactive bands p44 (ERK1, upper band) and p42 (ERK2, lower band) were first
detected as early as 15min post-infection with maximal levels achieved by 60min and
levels remained elevated up to 2h. ILlp-stimulated cells were investigated in parallel
(positive control) and a similar pattern of rapid activation was observed (Figure 5.2c).
Kinetically, IL-1 p stimulation was more rapid with maximal levels attained by 30min, and
complete inactivation 60min post stimulation. In contrast, a more sustained activation was
observed in the presence of both strains of bacteria (Figure 5.2a and b compared to c).
Detection of two immunoreactive bands, representing phosphorylated p54 (upper band) and
111
(a)
C 5’ 15’ 30’ 45’ 60’ 90’ 2hr Phospho-ERK
11 ERK
(b)
C 5’ 15’ 30’ 45’ 60’ 90’ 2hr
* = m p**- sh h  mttm mmm Phospho-ERK
m m m m m w rn r n m m m tm ERK
M
C 5’ 15’ 30’ 45’ 60’
Phospho-ERK
ERK
Figure 5.2 Activation of the ERK MAP kinase pathway. AGS cells were either co­
cultured with H. pylori (a) 60190, (b) 26695 ( lx l0 8cfu/ml) or treated with (c) IL-ip 
(20ng/ml) for up to 2h. Cell lysates were prepared and subjected to SDS-PAGE followed 
by western blotting with phospho-specific antibody for ERK1 (p44 upper band) and ERK2 
(p42 lower band). Blots were stripped and re-probed with non-phospho antibody specific 
for ERK MAPK for equal protein loading. The blots shown are representative of three 
individual experiments.
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p46 (lower band) were indicative of activation of the JNK MAPK pathway (Figure 5.3a). 
Compared to the ERK activation, induction of the JNK pathway was very modest. 
Phosphorylated JNK levels were evident at 30min and present until 60min post infection. 
p38 MAPK was also activated by H. pylori in AGS cells (Figure 5.3b). Phosphorylation of 
p38 was first detected at 45min post-infection with maximal levels between 60 and 90min 
diminishing at 2h.
5.2 Role of MAPK pathways in innate defence gene regulation (inhibitor studies)
Once the activation of all three MAP Kinases in our experimental model system was
established, a potential role for each in the regulation of IL-8 and p-defensin gene
expression was investigated. Initially, studies in the presence of pharmacological inhibitors
specific for each pathway were conducted. AGS cells were pre-treated with each inhibitor
for 30min prior to IL-lp or H  pylori- stimulation (Figure 5.4a). RT-PCR allowed the
assessment of gene expression. A representative of three experiments is shown. H. pylori-
mediated hBD2 expression was reduced by all of the MAPK inhibitors (Figure 5.4a). The
ERK inhibitor had the most dramatic effect on hBD2 expression (Lane C) followed by the
JNK inhibitor, SP100625 (Figure 5.4a; Lane B). The p38 inhibitor, however, was least
effective in decreasing hBD2 mRNA levels (Figure 5.4a; Lanes A). Inhibition of all three
MAPK pathways showed a significant reduction in IL-8 gene expression. Interestingly,
induction of Cox-2 (an innate defence gene) mRNA was observed in the presence of JNK
and ERK inhibitors (Lanes B and C). It is likely that this effect is due to increased stability
of the Cox-2 mRNA. Figure 5.4b represents the effects of MAPK inhibitors on IL-lp
stimulated innate immune gene expression. The p38 inhibitor had an inhibitory effect on
hBD2 expression (Lane A). In contrast the ERK inhibitors, PD98059 and U0126 were less
effective in causing a reduction of hBD2 defensin expression (Lanes B and C). Complete
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Figure 5.3 Slow and modest induction of JNK and p38 MAPK pathways by H. pylori.
H. pylori strain 60190 was used to infect AGS monolayers and cell lysates were subjected 
to Western Blot analyses using phospho-specific antibodies for (a) JNK p54 (upper band) 
and p46 (lower band), and (b) p38 MAPKs.
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Figure 5.4: Effect of MAPK inhibitors on (a) H. pylori- and (b) IL-ip-induced gene 
expression.
AGS cells were pre-treated with pharmacological inhibitors for each MAPK pathway prior 
to stimulation, (a) Lane A represents cells treated with bacteria+SB 203580, Lane B, 
bacteria+SP 600125; Lane C, bacteria+ERK inhibitor PD 98059, treated cells, (b) Lane A: 
IL-lp+SB 203580; Lane B and C, IL-ip+ERK inhibitors, PD 98059 and U0126.
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abrogation of IL-8 and Cox-2 mRNA was observed in the presence of p38 and ERK 
inhibitors.
To clarify the involvement of particular MAPK in P-defensin gene regulation, transient 
transfection experiments were conducted in parallel with RT-PCR studies. AGS cells were 
transfected with defensin-luciferase promoter constructs 24h prior to pre-treatment with 
MAPK inhibitors and exposure to bacteria or cytokines (Figures 5.5-5.7). The effect of 
each inhibitor is represented as a percentage of total promoter activation by wild type H  
pylori strain 60190 or cytokines. In accordance with RT-PCR experiments, H. pylori- 
mediated hBD2 promoter activity was significantly affected by the presence of inhibitors 
for all three MAPK pathways, with the most potent being ERK inhibitor which caused a 
reduction of more than 70% (Figure 5.5a). Interestingly, stimulation with IL-lp in the 
presence of inhibitors resulted in a very similar pattern of decrease in hBD2 promoter levels 
(Figure 5.5b).
Investigations into hBD3 promoter activity yielded comparable results as all three MAPK 
were implicated in H. pylori induction of hBD3 expression and yet again ERK MAPK 
seemed to be a critical player in mediating hBD3 expression in response to H. pylori 
infection (Figure 5.6a). Since H. pylori is known to interact with JAK/STAT signalling 
(Mitchell et al., 2004), and hBD3 promoter analysis has revealed the presence of STAT 
binding sites (Wolk et al., 2004), JAK inhibitor was also added to the co-culture system to 
determine a role for JAK/STAT signalling in H. pylori-mediated hBD3 expression. The 
presence of the JAK inhibitor induced a significant reduction in hBD3 (Figure 5.5a) 
promoter activity which was comparable to the effects observed in the presence of U0126. 
As IFNy is a known agonist for hBD3, it was used as a positive control and inhibitor 
studies exposed roles for only ERK and JNK but not p38 in cytokine-mediated promoter 
activity (Figure 5.6b).
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(a)
Figure 5.5: Potential role of MAP Kinase pathways in differential hBD2 regulation.
hBD2 promoter transfected AGS cells were pre-treated with specific inhibitors (p38; 
SB203580 25 pM, JNK; SP100625 50 pM, and ERK; U0126/PD98059 25 pM) and 
promoter activity quantified 8h post-stimulation. Results are presented as percentage 
activation of hBD2 promoter activity compared to (a) bacterial infection or (b) IL-ip 
stimulation alone.
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Figure 5.6: Potential role of MAP Kinase pathways in differential hBD3 regulation.
hBD3 promoter transfected AGS cells were pre-treated with specific inhibitors and exposed 
to (a) H. pylori infection or (b) IFNy stimulation. Results are presented as percentage 
activation of hBD3 promoter activity compared to (a) bacterial infection or (b) IFNy 
stimulation alone. Values are expressed as mean ±SEM from a representative of three 
experiments conducted in triplicates.
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In order to confirm IL-8 gene expression observed in RT-PCR findings in response to H. 
pylori, IL-8 promoter function was also assessed by luciferase-promoter assays. All three 
MAPK were involved in H. pylori -mediated IL-8 promoter regulation, but most prominent 
was the role of p38 where nearly 80% decrease in expression was detected in the presence 
of the inhibitor (Figure 5.7a). Both JNK and ERK inhibitors had very similar effects in 
reducing IL-8 promoter activity (more than 40% inhibition). Interestingly, the promoter 
activity observed in the presence of the different inhibitors during H. pylori infection was 
mirrored when cells were treated with IL-ip (Figure 5.7b), suggesting the involvement of 
all three pathways in both bacterial and cytokine-induced IL-8 expression. JNK and p38 
inhibitors reduced hBD2 and IL-8 expression levels to a similar magnitude whereas there 
was more of a contribution of the ERK pathway in mediating hBD2 rather than IL-8 
expression. RT-PCR findings suggest ERK is involved in H. pylori-induced hBD2 up- 
regulation whereas promoter analyses consistently implicated ERK MAPK pathway more 
than p38 and JNK in both hBD2 and hBD3 cytokine and H. pylori -mediated expression.
5.3 Activation of discrete MAP kinase pathways leads to differential P-defensin 
expression ,
Although the use of pharmacological inhibitors can estimate the potential role of each 
individual pathway, the complexity of cross-talk between various signal transduction events 
makes firm conclusions difficult. To gain better understanding of the exact contribution of 
individual MAP kinase pathways to p-defensin gene expression, two conditional kinases 
that stimulate defined MAP kinase pathways were utilised (Gamer et al., 2002, Todd et al., 
2004). HR1 cells are HEK293 cells expressing ARaf-l:ER* which specifically activates 
the ERK pathway following stimulation with 4-Hydroxytamoxifen (4-HT) (Figure 5.8) 
whereas HM3 cells are HEK293 expressing AMEKK3:ER*, which leads to strong
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Figure 5.7: Potential role of MAP Kinase pathways in IL-8 regulation.
(a) H. pylori- and (b) IL-lp- mediated IL-8 promoter activity was assessed in the presence 
of MAPK inhibitors. Results are presented as percentage inhibition of promoter activity 
compared to bacterial infection alone. Values are expressed as mean ±SEM from a 
representative of three experiments conducted in triplicates.
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Figure 5.8: Activation of ERK MAPK pathway.
HR1 epithelial cells expressing ARaf-l:ER* were stimulated with 4-Hydroxytamoxifen (4- 
HT; lOOnM) and cell lysates were subjected to SDS-PAGE followed by Western Blotting 
with a phosho-specific ERK antibody. Specific activation of the ERK pathway was 
observed with cells treated with 4-HT compared to untreated controls. Kindly performed by 
K. Ewings, Babraham Institute, Cambridge.
121
activation of the endogenous p38 and JNK pathways upon stimulation with 4-HT and a 
weaker activation of ERK (Todd et al., 2004). HR1 or HM3 cells were treated with 4-HT 
(lOOnM) for 8 or 24h prior to assessment of gene expression by RT-PCR to allow 
identification of pathways implicated in p-defensin expression in the absence of any 
stimuli. In order to negate effects of growth factors, experiments were conducted in the 
absence (or presence) of foetal bovine serum (FBS). Activation of ARaf-l:ER* failed to 
increase hBD2 expression regardless of the presence of FBS (Figure 5.9; left panel). In 
contrast, hBD3 was induced as early as 8h after activation of ARaf-l:ER*, in the absence of 
FBS, and expression was maintained at 24h irrespective of the presence or absence of 
serum. This finding confirmed a major role for the ERK pathway in hBD3 gene expression, 
in contrast the data clearly suggests that ERK activation alone is not sufficient to induce 
hBD2.
Activation of AMEKK3:ER* in HM3 cells resulted in marked increased expression of both 
hBD2 and hBD3 (Figure 5.9; right panel). hBD3 expression was apparent at 8h with further 
increase noted at 24h. The magnitude of response was slightly weaker in the absence of 
FBS. In contrast, induction of hBD2 expression was slower as it was only observed at 24h 
with weaker induction in the absence of FBS. The greater expression of hBD2 and hBD3 
by AMEKK3:ER* compared to ARaf-lER* cells raised the possibility that p38 and/or JNK 
may also contribute to the up-regulation of p-defensins.
The role of ERK pathway in hBD3 expression was further highlighted utilising U0126 
which reduced hBD3 levels to those observed in control unstimulated cells (Figure 5.10; 
left panel). These experiments suggest unequivocally that the ERK pathway is both 
necessary and sufficient for hBD3 gene expression in the absence of other signalling 
events. In contrast, the ERK pathway alone was unable to induce hBD2 expression.
To further dissect the contributions of p38 and JNK MAPK pathways in mediating
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Figure 5.9 Activation of ERK MAPK pathway is sufficient for hBD3 but not hBD2 
gene expression.
HR1 cells (expressing the ARaf-l:ER*, left panel) and HM3 cells (expressing
I
AMEKK3:ER*, right panel) were stimulated with 4-HT for a period of 8h or 24h in the 
presence or absence o f serum. P-defensin gene expression was evaluated by RT-PCR and a 
gel from a representative o f three independent experiments is shown.
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Figure 5.10 JNK MAPK is involved in regulation of both hBD2 and hBD3 expression.
HR1 cells and HM3 cells were pre-treated with pharmacological inhibitors for ERK 
(U0126), p38 (SB203580) and JNK (SP600125) pathways for lh prior to addition of 4-HT 
for 8h. Gene expression was assessed by RT-PCR. Treatment of HM3 cells with 4-HT + 
SP600125 (last lane; right panel) caused abrogation of hBD2 and hBD3 expression. A 
representative gel is shown.
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defensin gene expression, inhibitors prior to and during activation by 4-HT were used. As 
shown in Figure 5.10 (right panel) the presence of the JNK inhibitor SP600125 completely 
abolished the induction of hBD2, whereas the p38 inhibitor SB203580 had little effect. 
This result was reflected to a similar degree in hBD3 expression. In summary, these 
experiments highlighted a role for the JNK, but not the p38, signalling pathway in hBD2 
and hBD3 regulation and also indicated that the ERK pathway could act alone to increase 
hBD3 expression.
5.4 Conclusions
To maintain tissue homeostasis in health and disease, integration of multiple signals must 
occur in order for an appropriate response to be generated. The many players involved in 
MAP Kinase regulation and activation highlights the complexity of cross-talk involved and 
this complexity was further emphasised in these experiments employing pathway-specific 
inhibitors.
Use of pharmacological inhibitors implicated all three pathways to varying degrees in both 
hBD2 and hBD3 gene regulation. RT-PCR analyses for hBD2 suggested ERK is required 
for induction when cells were exposed to H. pylori and transfection studies indicated that 
ERK pathway seemed to play a role in both cytokine and bacterial-mediated p-defensin 
expression. Additionally, regulation of the host innate immune response upon challenge 
with H. pylori as a broad response was studied; hence expression of IL-8 and Cox-2 was 
investigated as both are critical genes implicated in H. pylori disease. IL-lp and H. pylori- 
mediated IL-8 expression was diminished by JNK, p38 and ERK inhibitors, in contrast, 
cytokine stimulation of COX-2 was abrogated by p38 and ERK inhibitors whereas bacterial 
stimulation was only lessened by the p38 inhibitor. This data indicates there are discrete
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signalling mechanisms which are stimuli-specific involved in the regulation of this subset 
of innate immune genes.
The inclusion of the JAK inhibitor revealed a role for the JAK-STAT signalling pathway in 
H. /Ty/on'-mediated hBD3 regulation. This finding correlates with the presence of STAT 
binding sites in the hBD3 promoter (Wolk et al., 2004) and IFNy, which typically signals 
via JAK-STAT pathways, being a potent agonist of hBD3. IFNy production is characteristic 
of a Thl immune response observed during H. pylori infection and a recent study has 
documented the presence of the bacterium caused a reduction in IFNy-induced STAT1 
DNA binding (Mitchell et al., 2004). This result was independent of the cagA, cagE, and 
vacA status of the infecting H. pylori strain and these findings taken together with the 
involvement of JAK-STAT signalling in hBD3 expression may represent a mechanism by 
which the bacterium can modulate/decrease host hBD3 antimicrobial response, thus aiding 
persistent colonisation.
HR1 and HM3 cells were employed to single out MAPK pathways in P-defensin regulation
as any firm conclusions from the pharmacological studies were not made. This novel
strategy allowed us to selectively activate individual MAPK pathways in the absence of any
other signalling event. The most contrasting data between the inhibitor studies and the
conditional mutants was obtained for hBD2 gene expression as the use of U0126 suggested
ERK activation to be involved in both hBD2 and 3 gene expression (Figures 5.5 and 5.6)
however, ERK activation alone was unable to induce hBD2 expression (Figure 5.9). This
important finding suggests that ERK pathway must synergise or cross-talk with other
pathways to modulate hBD2 expression during H  pylori infection. In contrast, ERK
pathway alone was sufficient to induce hBD3 expression. Addition of specific inhibitors in
HM3 cell system revealed a significant role for the JNK pathway in P-defensin expression,
whereas p38 was found to be unnecessary. The finding implicating JNK but not p38 in
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induction of (3-defensins represents another discrepancy between the results obtained for 
hBD2 expression with the MAPK inhibitors in AGS cells and the use of the conditional 
kinase HEK 293 cell line, suggesting that unlike the simple and limited pathway(s) in the 
HEK 293 system, the presence of infection is likely to initiate many overlapping signalling 
pathways involved in molecular cross-talk.
Unlike NF-kB activation, it is unclear whether activation of the MAPK by H. pylori is 
dependent upon an intact CagPAl, as one study has documented induction of MAPK 
pathways by CagPAl negative strains but to a lesser extent that wild type strains (Keates et 
al, 1999). Another study showed that strains specifically lacking CagA or strains that are 
mutated in cag genes encoded by the CagPAl, do not induce MAP kinase activity (Meyer- 
ter-Vehn et al, 2000). Such evidence implies that modulation of host epithelial cell signal 
transduction responses may contribute to pathogenesis of disease (Peek, 2001).
A similar dependency for JNK but not the p38 or ERK pathway in hBD2 expression has 
also been observed during E.coli Nissle 1917-mediated infection of intestinal epithelial 
cells (Wehkamp et al., 2004). Conversely, Pseudomonas aeruginosa-mediated hBD2 
induction in human keratinocytes was blocked by treatment of NF-kB, JNK and p38 
inhibitors but not ERK inhibitors (Wehkamp et al., 2006).
Previous studies in oral epithelia with the periodontal bacterium Fusobacterium nucleatum,
have indicated that the MAP kinases are involved in hBD2 regulation but NF-kB is not
(Krisanaprakomkit et al, 2002). Further to this, hBD2 induction by both commensal and
pathogenic bacteria was partially or completely blocked by inhibitors of the JNK and p38
pathways whereas only hBD2 up-regulation by pathogenic strains was blocked by
inhibitors of NF-kB in both oral and foreskin keratinocytes (Chung and Dale, 2004). These
findings suggest that epithelial cells share common signalling mechanisms to distinguish
between the distinct pathways utilised by commensal and pathogenic bacteria. Collectively,
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the results from all these investigations highlight the differential signalling pathways 
employed by different bacterial species at distinct anatomical sites.
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CHAPTER 6 
A Potential Role for H. pylori-induced 
EGF Receptor Transactivation in hBD3
Expression
129
6.0 Background
The epidermal growth factor receptor (EGFR) belongs to the ErbB family of receptor 
tyrosine kinases and plays a critical role in mediating the regulation of cell proliferation, 
survival and wound healing (Stein and Staros, 2000). Binding of a growth factor ligand to 
its receptor initiates a cascade of phosphorylation events orchestrated by protein kinases, 
ultimately leading to activation of transcription factors and changes in gene expression. 
EGFR is a 170kDa cell surface glycoprotein present in many cell types, its structure 
comprises three main regions; i) a glycosylated extracellular ligand-binding domain, ii) a 
hydrophobic transmembrane domain, and iii) a cytoplasmic conserved protein tyrosine 
kinase domain (Castillo et al., 2004).
There are 11 ligands identified for this family of receptors to date including EGF, 
transforming growth factor-a (TGFa), HB-EGF (heparin-binding) and amphiregulin 
(Olayioye et a l , 2000) and many of these are expressed as membrane-bound proteins 
themselves. Upon proteolytic cleavage the ligands become available for receptor binding 
and are able to initiate downstream signalling events such as the involvement of the MAPK 
or PI3K/Akt pathways (Bazley and Gullick, 2005). The important role in regulating cellular 
growth and developmental processes is highlighted by the hyperactivation of EGFR leading 
to cancerous tumor growth. The loss of regulation of normal processes may occur via 
several different mechanism(s) such as overexpression of receptor, autocrine 
overproduction of ligands or EGFR mutations (Castillo et al., 2004). Such mechanisms 
may result in increased cell growth and proliferation with a decrease in apoptosis.
Divergent signalling responses have been reported during infection with cag± and/or con­
strains, particularly cag+ strains preferentially activating the MAPK, NF-kB and proto­
oncogenes c-fos and c-jun (Glocker et al., 1998, Keates et al., 1999, Meyer-ter-Vehn et al.,
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2000). The induction of genes involved in immunity, cell growth, proliferation and 
apoptosis may help to explain why individuals infected with cag+ strains are more likely to 
develop gastric cancer (Peek, Jr., 2002). Several studies have revealed transactivation of 
the epidermal growth factor receptor (EGFR) by Helicobacter pylori and in addition, 
gastric expression levels of EGFR ligands (EGF, HB-EGF) and EGFR itself are elevated 
(Fischer et al., 2003, Keates et al., 2001, Wallasch et al., 2002). The relevance of the 
EGFR pathway in wound healing processes and mucosal repair makes it a particularly 
critical pathway for further investigation (Barnard et al., 1995, Leahy, 2004).
6.1 Epidermal Growth Factor Receptor (EGFR) transactivation by H. pylori 
The experiments so far have implicated NODI as the upstream mediator of NF-kB-induced 
hBD2 but not hBD3 gene expression (Chapter 4). The lack of NF-kB binding sites in the 
promoter region of hBD3 in addition to the NF-kB inhibitor studies ruled out a role for NF- 
kB in the regulation of hBD3. This prompted exploration into potential candidate upstream 
receptors in driving inducible hBD3 expression. The involvement of ERK MAPK in hBD3 
but not hBD2 up-regulation (Chapter 5) led to the hypothesis that EGFR may be an 
upstream mediator of hBD3 expression since it is known to be an upstream signalling event 
of ERK MAPK.
Previous reports have demonstrated the ability of H. pylori to activate EGFR signal
transduction cascades in gastric epithelial cells (Keates et al., 2001, Pai et al., 1998,
Romano et al., 1998, Wallasch et al., 2002). In addition, gastric expression levels of EGFR
ligands (EGF, HB-EGF and amphiregulin) and EGFR itself are elevated during infection
both with cag+ and cag- strains (Keates et al., 1999, Romano et al., 1998, Wallasch et al.,
2002). Prior to investigating the role of EGFR in bacterial-mediated hBD3 expression,
transactivation status of EGFR during H. pylori infection in this experimental model system
131
had to be established. Tyrosine phosphorylation of EGFR was followed by Western 
blotting utilising an antibody that recognises tyrosine phosphorylated proteins. Specificity 
of EGFR was confirmed by reprobing blots with an EGFR-specific antibody. Activation of 
EGFR was observed as early as lh post-infection (Figure 6.1). Time-dependent 
phosphorylation of EGFR was followed up to 4h post-infection. Selective inhibition of 
EGFR was verified by addition of a neutralising antibody and pharmacological inhibitor 
(AG1478; 3pM). In the presence of inhibitory reagents tested, transactivation of EGFR was 
blocked, confirming specificity of reaction. Cells were also treated with 50ng/ml of 
recombinant EGF, included as a positive control.
6.2 Potential role of EGFR-activation in mediating P-defensin gene expression
Next, the role of EGFR activation in mediating P-defensin gene expression was examined. 
AGS cells were either left alone or pre-treated with several inhibitory reagents for EGFR 
for 30-60min prior to H. pylori infection. A neutralising antibody specific for EGFR and 
two EGFR-specific pharmacological inhibitors, leading to inhibition of subsequent 
downstream signalling events, the competitive inhibitor AG 1478 or the irreversible 
inhibitor PD168393 were used. Figure 6.2 depicts EGFR signalling pathway and in 
particular the target of the two inhibitory reagents is highlighted.
Specific inhibition of EGFR either in the presence of the inhibitors or neutralising EGFR
antibody resulted in significant reduction in hBD3 mRNA was found (Figure 6.3). The
most effective inhibition was observed by the neutralising antibody (10(ig/ml) where hBD3
gene expression was reduced by 60%. The two inhibitors were similarly potent in inhibiting
hBD3 as expression levels were decreased by 40-50%. Interestingly, no effect of these
agents was demonstratable on H. /^/on-mediated hBD2 gene expression (Figure 6.3). As
expected, these findings ruled out a role for EGFR in regulating hBD2 gene expression but
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Figure 6.1: Time-dependent increase in EGFR tyrosine phosphorylation by H. pylori.
n
AGS cells were infected with wild type H. pylori (1x10 cfu/ml) for up to 4h and cell 
lysates taken at hourly intervals were subjected to immuno-blotting. Tyrosine 
phosphorylation was followed with a phospho-specific antibody followed by EGFR 
specific antibody to confirm equal loading. Selective inhibition o f EGFR phosphorylation 
was observed in the presence of AG 1478 (AG), a specific inhibitor, and EGFR neutralising 
antibody (aEGF) 2h post-infection. Recombinant EGF (50ng/ml; lh) was included as a 
positive control.
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in contrast, provided the first clear indication for EGFR-mediated hBD3 regulation in our 
model of infection.
EGFC2S
AG1478 PD168393
STAT1
Figure 6.2 AG1478 and PD168393 target EGFR and downstream signalling cascades.
6.3 Potential role of EGFR-activation in mediating p-defensin peptide expression
In order to substantiate the gene expression findings, peptide analysis was conducted by 
Western Blotting. There was minimal peptide detected in control uninfected cells but both 
hBD2 and hBD3 peptides were induced upon infection with wild type H. pylori (Figure 
6.4), 24h post-infection. The increase in hBD3 protein levels during infection was 
abrogated in the presence of AG 1478, however, inhibition of EGFR pathway did not affect 
hBD2 peptide levels. Recombinant peptides were included as positive controls (Figure 6.4).
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Figure 6.3: H. pylori-mediated hBD3 expression is dependent on EGFR signalling.
AGS cells were pre-treated with selective inhibitors for EGFR, AG1478 (3 pM), PD168393 
(2 pM) or neutralising antibody (lOpg/ml) for 30-60min before co-infection with H. pylori 
strain 60190. Induction o f hBD2 and hBD3 mRNA was assessed 8h post-infection by RT- 
PCR. P-defensin levels were normalised to GAPDH and expressed as fold induction 
compared to uninfected control cells. Data shown were obtained from three independent 
experiments and results are presented as mean values ± SEM. Statistical significance was 
determined by t- test, * p < 0.02.
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Figure 6.4: EGFR transactivation is a critical upstream signalling event in H. pylori- 
mediated hBD3 expression.
Control un-infected and 24h post-infected AGS cell lysates and supernatants were 
subjected to 16% Tris-Tricine SDS PAGE prior to detection o f secretory hBD2 and hBD3 
(cell lysate) peptides by Western Blotting. 150pg protein was loaded as determined by 
Bradford assay and recombinant peptides were included as positive controls. EGFR 
inhibitor, AG1478 (3pM) caused a significant decrease in hBD3 but not hBD2 protein 
levels.
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6.4 Conclusions
Collectively, these experiments support the notion that transactivation of the EGFR and 
subsequent downstream signalling cascades may play a critical role in hBD3 gene and 
peptide expression with a minimal role in hBD2 regulation during H. pylori infection.
The elucidation of the EGF—► Ras—►Raf-l—► MEK—► ERK pathway for proliferation 
and differentiation of cells (O'Neill and Kolch, 2004; Figure 6.2), identifies a potential 
pathway for the ERK-mediated hBD3 expression observed in our study. A role for EGFR 
was successfully determined, however, the ligand involved was not established in this 
study. Other studies implicate metalloprotease cleavage of HB-EGF in EGFR 
transactivation during H. pylori infection (Keates et al., 2001, Wallasch et al., 2002).
Keates and colleagues have demonstrated EGFR-mediated Ras activation is an upstream 
signalling event leading to ERK activation in H. pylori infected AGS cells (Keates et al., 
2005), which supports the established EGFR-ERK pathway engagement during H. pylori 
infection and that may also be involved in hBD3 gene regulation. Interestingly, a recent 
study has implicated EGFR transactivation in hBD3 gene expression in a skin model of 
inflammation (Sorensen et al., 2005). P-defensin expression was induced in epidermal 
cultures which were exposed to mononuclear blood leukocytes stimulated with several 
PAMPs. The induction of hBD3 was inhibited by the addition of a neutralising antibody to 
EGFR and furthermore, the ligands responsible for the up-regulation of this inducible 
peptide in keratinocytes were identified as TGFa being the most potent followed by EGF, 
HB-EGF and amphiregulin. Unlike the study conducted by Sorensen et al, the present study 
investigated the mechanism of p-defensin induction during an infection model, which will 
undoubtedly involve complex molecular cross-talk and more than one signalling pathway 
occurring at any given time.
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Some studies suggest AMPS such as LL-37 and HNPs may directly act as inducers of 
EGFR transactivation, possibly by mediating metalloprotienase cleavage of membrane- 
bound ligands (Aarbiou et al., 2004, Tjabringa et al., 2003). This may represent a dual role 
for AMPs in triggering an innate immune response in addition to being effective 
antimicrobials. No studies to date have suggested such a role for the P-defensin family.
More recently, not only did the transactivation of EGFR lead to increased hBD3 
expression, but also induction of two other AMPs; neutrophil gelatinase-associated 
lipocalin (NGAL) and secretory leukocyte protease inhibitor (SLPI) was also observed in 
skin (Sorensen et al., 2006). The EGFR-mediated up-regulation of hBD3 in this setting was 
activated by HB-EGF and led to an increased antibacterial activity against Staphylococcus 
aureus.
Like NF-xB-mediated inflammatory responses, I propose that transactivation of EGFR 
leading to production of AMPs also presents a major innate immune axis responsible for 
providing a sterile environment and protection against microbial invasion and colonisation 
during wound healing.
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CHAPTER 7 
Discussion
The Gram-negative bacterium Helicobacter pylori colonises the gastric epithelium and 
causes acute and chronic inflammation of the stomach (gastritis). It is strongly associated 
with peptic ulceration, MALT lymphoma and adenocarcinoma (Blaser, 1996). H. pylori 
possesses several virulence determinants which, together with environmental factors, are 
considered to affect and modulate subsequent host innate and adaptive immune responses. 
It is becoming increasingly evident that clinical manifestations of H. pylori infection are 
resultant from cumulative effect of multiple interactions between the bacterium and host. 
Antimicrobial peptides of the P-defensin family are expressed at epithelial surfaces where 
they play an integral role in mucosal defence (Biragyn, 2005, Ganz, 2005, Klotman and 
Chang, 2006, Pazgiera et a l , 2006, Selsted and Ouellette, 2005). Human beta defensin 1 
(hBDl) is constitutively expressed through the GI tract, suggesting a surveillance-like role 
for this peptide, whereas hBD2 and -3 are inducible upon infection (Harder et al., 2000, 
Harder et al., 2001, O'Neil et al., 1999, Wada et al., 1999, Wehkamp et al., 2004) and 
inflammation. H. pylori can cause modulation in the expression of all three defensins 
(Bajaj-Elliott et al., 2002, George et al., 2003). The extensive use of commercial antibiotics 
has led to the emergence of resistant bacterial strains that pose a major health burden. As P- 
defensins are endogenous antibiotics, proven to be effective in killing a range of micro­
organisms, extensive research is currently being conducted in exploring the potential of P- 
defensins as novel therapeutic agents against infection.
Current guidelines indicate first-line therapy for treating H. pylori infection comprises a
combination of any two antibiotics (amoxicillin, clarithromycin or metronidazole) with a
proton pump inhibitor (PPI) or ranitidine bismuth citrate (RBC) (Di Mario et al, 2006).
However, this regimen fails in 20% to 40% of patients (Vilaichone et al, 2006) and
antibiotic resistance is one of the prominent causes for treatment failure, in addition to poor
compliance, short duration of therapy, and drug-related side effects. This increase in
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resistant bacterial strains has led to growing concern over effective eradication of this 
persistent pathogen and hence the search for novel antimicrobials.
We and others have previously highlighted the potent bactericidal activity of human |3- 
defensin 2 and 3 against H. pylori in vitro (George et al., 2003, Hamanaka et al., 2001). To 
address the issue of p-defensins being bactericidal in vivo, experiments have shown that 
their antimicrobial potencies are minimally affected in the presence of acidic conditions 
(pH 2-4) therefore no inactivation should occur due to the low pH in the human stomach. 
Similarly, killing assays have been performed to determine synergistic effect not only 
between the P-defensins but also with other AMPs such as LL-37 and lysozyme against H. 
pylori, a potential scenario in vivo. This data raises the question as to “why P-defensins if 
so potent in vitro, are not able to clear the infection in vivo?” One may hypothesise that H. 
pylori may manipulate host anti-microbial/p-defensin levels in such a way that insufficient 
amount of peptides are produced that are unable to clear infection. This may be explained, 
in part at least, if individuals with high peptide levels show greater ability to reduce and 
clear infection compared to individuals who are low P-defensin producers. Recent evidence 
suggesting P-defensin gene copy numbers can vary between 2 and 12 (Linzmeier and Ganz, 
2005) and that the copy number is the major determinant of protein produced adds credence 
to our suggestion. Secreted p-defensins along with other AMPs provide an antimicrobial 
gradient from the mucosal surface to the lumen and the amount of peptides are likely to 
determine the concentration of this gradient. The strength of this gradient is likely to be 
crucial in allowing H. pylori to successfully attach and attack the epithelial surface. This 
phenomenon provides at least one explanation for the observed variation in H. pylori- 
related diseases amongst a population of individuals with unique genotypes and therefore 
corresponding phenotypes.
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As the host antimicrobial response is one of the initial host factors encountering pathogens 
at mucosal surfaces, further insight into how H. pylori modulates this response to its 
advantage was required. Therefore, the major aim of this thesis was to a) delineate the role 
of bacterial virulence determinants in modulating p-defensin expression and b) to identify 
the critical signal transduction events involved in p-defensin regulation. The latter was 
important as identification of major players that determine the ‘robustness’ of host innate 
antimicrobial immunity to infection may open new avenues for therapeutic intervention. 
Intial studies confirmed the presence of hBDl and -2 gene expression in gastric epithelial 
cells during H. pylori infection. Furthermore, hBD3 gene expression and both hBD2 and -3 
peptide induction via Western Blotting in response to infection in AGS cells were 
demonstrated. Kinetic studies showed rapid induction of hBD2 mRNA, maximal 
expression was observed 6h post infection (Figure 3.2a). IL-8 also showed characteristics 
of an early innate immune response gene with comparable timing to hBD2, suggesting that 
hBD2 and IL-8 are induced rapidly to provide an acute immune response to infection. Since 
hBD2 is now known to also exhibit chemotactic properties for cells of the adaptive immune 
system, in this case, hBD2 may have a dual role in vivo by recruiting other immune cells in 
addition to being an antimicrobial peptide.
In order to address the first main hypothesis of this investigation, isogenic mutants of H.
pylori strain 60190 were utilised to determine the potential role of bacterial virulence
factors in modulating epithelial p-defensin expression. Induction of hBD2 was found to be
dependent upon an intact bacterial secretion system (Figure 3.4). The use of various
bacterial strains including CagPAl-ve clinical strain, J150, verified this result (Figure 3.3).
Published work with isogenic mutants (including CagE) have implicated a crucial role for
an intact secretion system, but not the translocation of bacterial CagA, in eliciting
activation of the immediate early response transcription factor, NF-kB and subsequent gene
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expression of various proinflammatory molecules such as IL-8, IL-lp and TNF-a (Maeda 
et al, 2001, Crabtree et al., 1999, Fischer et al., 2001, Munzenmaier et al., 1997, Naumann, 
2000, Selbach et al., 2002, Viala et al., 2004). One study to date has documented a role for 
H. pylori CagPAl in the induction of hBD2 mRNA (Wada et al., 1999). In the present 
study, a minimal role for both CagA and VacA virulence factors was found in modulating 
epithelial antimicrobial responses despite the dramatic phenotype changes caused by both 
toxins. This suggests some divergence in epithelial signalling pathways that dictate innate 
immune responses versus cytoskeletal changes caused by CagA and VacA (humming bird 
phenotype and vacuolation respectively). Exclusion of the injected CagA protein as a 
bacterial factor responsible for p-defensin gene expression led us to speculate the nature of 
the bacterial constituent responsible for instigating epithelial innate immune responses. 
Further delineation of these events is likely to be beneficial for successful future drug 
design.
Prior to investigating mechanism(s) regulating epithelial p-defensin expression, it was 
important to establish hBD2 induction in our cell system was directly due to the bacterium 
and not a secondary effect to production of IL-lp, a well-known agonist for hBD2. 
Minimal effect of IL-IRa on bacterial-mediated defensin expression was observed (Figure 
4.8). This finding suggests the bacteria are directly exploiting host innate signalling 
pathways to modulate epithelial defensin expression. In spite of this, it is likely that IL-lp 
paracrine effects following release from inflammatory cells would be an additional stimulus 
to epithelial cell hBD2 expression in vivo in the gastric mucosa.
Experiments investigating expression and regulation of hBD2 and -3 suggested different 
kinetics of expression for the two antimicrobials. Compared to the rapid (6h) expression of 
hBD2, hBD3 mRNA up-regulation was slower with levels increasing between 12-24h post­
infection. This fnding provided the first indication of differential regulatory mechanism(s)
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for hBD2 and hBD3 gene expression. The differing kinetics suggests provision of a more 
global host antimicrobial blanket rather than a potent short burst may be more beneficial to 
the host in protecting itself against an invading microbe. Physiologically, overlapping 
antibacterial functions of hBD2 and -3 is likely to provide more sustained and effective 
antimicrobial barrier and it would be interesting to study this further in the context of how 
lysozyme and LL-37 impact and modify the strength of this protective shield.
Several binding sites for NF-kB and AP-1 in hBD2 promoter suggest multiple signalling 
pathways can impact on its gene regulation and their involvement is likely to differ 
depending upon the initiating stimulus (Krisanaprakomkit et al., 2000, Krisanaprakomkit et 
al., 2002). As eukaryotic cells commonly respond to extracellular signals via the activation 
of the MAP Kinase pathways and NF-kB, it was pertinent to study these signalling 
pathways and in particular, a specific aim of this study was to delineate the signal 
transduction events involved in the regulation of H. pylori-epitheWal defensin cross-talk. I 
hoped that this study may provide further insight into signalling events that may be 
considered as future therapeutic targets for modulating host immunity to infection.
Although the transcription factor NF-kB has been implicated in both IL-lp and H. pylori- 
mediated hBD2 gene expression, very little is known about the regulation of hBD3 and 
therefore it was sought to identify the regulatory mechanisms involved in hBD3 expression 
during H. pylori infection. A minimal role for NF-kB in H  pylori-mediated hBD3 
expression was found (Figure 4.7), which was in agreement with promoter analyses 
revealing no NF-kB binding site in the promoter region. The lack of involvement of NF-kB 
and thus lack of involvement of NODI in regulating hBD3 may help some way to explain 
the varying kinetics observed for NF-kB-dependent hBD2 expression compared to hBD3 
and is clearly a parameter defining the two subsets of innate immune genes.
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Owing to H. pylori being an extracellular pathogen, the trans-membrane TLRs seem to be 
ideal candidate host receptors to be involved in epithelial bacterial sensing. Surprisingly, 
this family in general is not being exploited by H. pylori at the epithelial surface. Not only 
gastric epithelium but intestinal epithelium is also hypo-responsive to Gram-negative LPS 
(Eckmann, 2006). As the gastrointestinal tract is in continuous contact with microbes 
(particularly the colon), one may speculate that hyporesponsivenss to LPS at the mucosal 
surface is a strategy employed by the host ensuring tissue homeostasis as otherwise, 
continuous detection of LPS from resident microflora would result in constant 
inflammatory activation, a scenario surely detrimental to health. At the same time, low 
biological activity of H. pylori LPS clearly suggests that the bacteria itself has evolved to 
minimise its detection by the host, a modification that must aid H. pylori in being persistent 
in asymptomatic individuals. Similarly, the bacterial flagellin protein has evolved with 
sequence changes that allow it to escape detection by host epithelial TLR5 and yet maintain 
motility (Andersen-Nissen et al., 2005), a crucial process that the bacteria must undergo to 
successfully cross the protective mucus lining prior to epithelial adherence. Further studies 
investigating bacterial modifications that allow enteropathogens to successfully 
colonisation the GI tract are eagerly awaited.
In order to delineate the signal transduction pathways mediating hBD expression, it was 
imperative to clarify a role if any, for TLRs in mediating NF-kB activation leading to 
hBD2 gene expression during H. pylori infection. By disruption of host cell signalling 
complexes integral to TLR and IL-lp transduction and subsequent inhibition of 
downstream signalling, no effect of these pathways on bacterial-mediated hBD2 expression 
was observed (Figure 4.9). This clearly demonstrated that H. pylori has evolved 
mechanism(s) that allow it to circumvent any recognition and activation by epithelial 
TLRs.
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A second family of PRRs has been described to play crucial role in epithelial host innate 
immune responses to infection, the cytoplasmic NOD proteins (Inohara et al., 2002, 
Philpott and Girardin, 2004, Strober et a l, 2006). Although NODI but not NOD2 mRNA 
was detected in AGS gastric epithelial cells (Figure 4.10), expression of both NODI and 
NOD2 receptors is present in the gastric epithelium of H. pylori-positive individuals 
(Rosenstiel et al., 2006) and importantly, a significant role for NODI in the detection of H. 
pylori by epithelial cells has been reported (Viala et al., 2004). NF-kB activation was 
dependent upon the presence of an intact cagPAI, indicating the type IV secretion system is 
required for the intracellular delivery of bacterial iE-DAP. As the TLRs were ruled out by 
preceding experiments, it was hypothesised that NODI may play a role in H. pylori- 
mediated P-defensin gene regulation. Experiments utilising siRNA for NODI implicated 
NODI engagement in H. /ry/on-mediated hBD2 expression (Figure 4.12 and 4.13). Since 
hBD2 expression was found to be exclusively dependent upon an intact secretion system, 
this fits in with NODI receptor being responsible for its induction as H. pylori rarely 
invades cells and therefore the type IV secretion apparatus would be required for 
intracellular translocation of NODI ligand, iE-DAP. Any bacteria freely residing in the 
gastric mucus layer would remain in their niche undisturbed without triggering host innate 
immunity allowing persistent colonisation. However, if adherent CagPAI+ve bacteria 
became intimate with epithelial cells, it is possible that peptidoglycan from cell wall may 
‘leak’ through to host cells where the tri-peptide motif may bind NODI and initiate signals 
to activate the host innate immune response. Ultimately, the production of specific 
antibacterial agents such as p-defensins would be detrimental to the pathogenic micro­
organism but even without direct invasion of epithelial cells, the bacteria are capable of 
inducing p-defensin expression. One may also speculate that that the induction of AMPs
could be beneficial to persistent pathogens, as any transient infections caused by other
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bacterial species would be effectively killed by AMPs as they may not exhibit sophisticated 
mechanisms to subvert innate immunity.
Furthermore, murine experiments suggest a role for NODI in mediating mBD4 (an 
orthologue of hBD2) expression in vivo (Figure 4.14). It is a crucial step in the 
development of p-defensins as potential therapeutics to ascertain their in vivo functional 
relevance by complementing in vitro investigations. It is a fundamental finding to establish 
the PRR mediating production of theses AMPs in vivo, so that future efforts may be 
targeted accordingly. These findings provide evidence for the primary hypothesis in this 
study by linking impaired p-defensin expression to increased colonisation observed in the 
NODI KO mice (Viala et al., 2004). It is entirely possible that low mBD4 expression 
levels contribute to reduction in antimicrobial function, leading to the observed increase in 
colonisation in the murine stomach. In conclusion, these data highlight a key role for 
NODI in modulating host anti-microbial function in vivo.
As differential kinetics and contribution of NF-kB for hBD2 compared to hBD3 were
observed, it was not expected that both peptides are regulated by the same mechanism. So,
to delineate signal transduction events mediating hBD3 expression during H. pylori
infection another set of signalling pathways which play a vital role in infection and
inflammation, the MAPKs were investigated. The activation of MAPK pathways during H.
pylori infection has been well studied (Keates et al., 1999, Meyer-ter-Vehn et al., 2000,
Mitsuno et al., 2001, Naumann et al., 1999, Naumann and Crabtree, 2004, Torok et al.,
2005). Prior to establishing a role for the MAPK in P-defensin gene regulation, it was
pertinent to confirm the activation of MAP kinase pathways in our co-culture system
(Figure 5.1 and 5.2). In agreement with previous findings, activation of all three MAPK
pathways was observed and the use of pharmacological inhibitors implicated all three
pathways to varying degrees in both hBD2 and hBD3 gene regulation. RT-PCR analyses
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for hBD2 and IL-8 indicated discrete signalling mechanisms which were stimuli-specific 
are involved in the regulation of this subset of innate immune genes. Luciferase promoter 
constructs for the 0- defensins indicated that ERK pathway seemed to play a role in both 
cytokine and bacterial-mediated hBD2 and -3 expression, whereas p38 pathway was not 
implicated in cytokine-mediated hBD3 expression (Figure 5.4 and 5.5). Any firm 
conclusions by singling out any particular pathway in p-defensin expression were not able 
to be established.
By selectively activating individual MAPK pathways (utilising conditional kinase cell- 
lines) in the absence of any other signalling event ERK activation alone induced hBD3 but 
not hBD2 expression. This important finding suggests that ERK pathway must synergise or 
cross-talk with other pathways which are likely to be activated during infection to modulate 
hBD2 expression. These studies so far implicated NODI-dependent NF-kB activation and 
the JNK pathway in hBD2 gene regulation. In contrast to hBD2, hBD3 expression was 
NODI independent but ERK- and JNK pathway-dependent. Like preceding findings in this 
study the involvement of ERK yielded another difference in the regulation of hBD2 
compared to hBD3, which provided a clue as to what upstream effectors may be regulating 
hBD3. As the ERK pathway can be activated by cagPAI-ve strains (Naumann and 
Crabtree, 2004), it was hypothesised that the EGF receptor is the most likely candidate 
upstream of the ERK pathway (shown by Keates et al, 2005) and hBD3 expression. 
Indeed, a role for EGFR transactivation in hBD3 mRNA and peptide expression was 
identified (Figures 6.3 and 6.4), in this model of infection. I propose EGFR may also 
function as a critical regulator of a subset of innate response genes with hBD3 a prominent 
member.
The molecular events leading to EGFR transactivation during infection were not
investigated in the present study although metalloprotease cleavage of HB-EGF may play a
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role (Wallasch et al., 2002). Importantly, recent advances in therapy for cancer have 
targeted EGFR signalling and in particular utilised pharmacological inhibitors and 
monoclonal antibodies at the clinical level (Mendelsohn, 2002). This would be a significant 
treatment in the subset of H. ^y/on-infected individuals which are suffering form gastric 
cancer. However, the targeting of the EGFR pathway would prevent production of 
antimicrobial hBD3, which may provide critical protection in wound healing phase of 
infection by killing any opportunistic pathogenic micro-organisms whilst the epithelial 
barrier is most vulnerable. Recent advances are being made into investigating the killing 
mechanisms of AMPs to use them as anti-cancer therapy (Papo and Shai, 2005), as 
damaging the cell membrane would be an effective way of eliminating cancerous cells. 
However, further studies into these potential applications are required to determine the 
molecular mechanisms underlying anti-cancer activity.
Despite the effectiveness of p-defensins in killing H  pylori, the question remains how this 
gastric pathogen is capable of persisting in the presence of host immune responses. In 
addition to the virulence factors and host genetic factors discussed earlier, there are several 
other determinants contributing to the success of H. pylori as a persistent coloniser of the 
human stomach. An essential colonisation factor is the acquisition of nutrients, namely 
iron, as mutants lacking in the expression of ferritin are unable to colonise (Waidner et al., 
2002). This allows the bacterium to survive beyond the initial colonisation period where it 
utilises urease to alkalinise the acidic microenvironment of the stomach and establish its 
niche. Also, the production of its own antimicrobial agent highlights this bacterium’s 
sophistication as this ability would enable the clearance of other potential competitive 
pathogens (Fu et al., 2004).
Importantly, previous work defining a role for the murine BD1 utilising deficient mice has
shown increased susceptibility to certain pathogens (Morrison et al., 2002, Moser et al.,
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2002) indicating these peptides are not necessarily redundant in their nature and are critical 
contributors of host defence against infection in vivo. Another murine study investigating 
P-defensin expression after vaccination with a construct encoding H. pylori urease enzyme 
observed an increase in mBDl in the stomach of immunised mice (Hatzifoti et al., 2006). 
In addition to the adaptive immune system being protective by production of H  pylori- 
specific antibody and T-cell proliferation, it seems that the induction of mBDl may aid in 
limiting colonisation at the mucosal surface thus conferring protection through host innate 
immune responses. In this case, not only is defensin production a first line defence, it 
appears to be involved in a more complex global immune response intertwining innate and 
adaptive immunity. These studies collectively draw attention to the importance of p- 
defensins in host defence in vivo and complement in vitro work implicating AMPs as 
significant components of innate immunity.
In conclusion, this study has shown that dynamic modulation of host epithelial anti­
microbial immunity occurs in response to H. pylori. The bacterium indulges in direct 
epithelial cross-talk exploiting host responses in order to persistently colonise the gastric 
epithelium. The distinct regulatory mechanisms and overlapping functions of hBD2 and -3 
try to provide an antimicrobial shield through out the inflammatory and wound healing 
phase of infection, in individuals infected with more virulent strains and low defensin 
expression the antimicrobial shield may prove to be insufficient leading to greater persistent 
colonisation culminating in greater clinical manifestations and complications.
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